Page last updated: 2024-10-31

mitotane and Adrenocortical Carcinoma

mitotane has been researched along with Adrenocortical Carcinoma in 257 studies

Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.

Adrenocortical Carcinoma: A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.

Research Excerpts

ExcerptRelevanceReference
"Adjuvant treatment with mitotane is commonly used after resection of adrenocortical carcinoma; however, treatment remains controversial, particularly if risk of recurrence is not high."9.69Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. ( Arlt, W; Bancos, I; Basile, V; Baudin, E; Berchialla, P; Berruti, A; Bertherat, J; Beuschlein, F; Bourdeau, I; Bovis, F; Bruzzi, P; Canu, L; Caron, P; Chabre, O; Chortis, V; Cosentini, D; Decoudier, B; Dusek, T; Ettaieb, MH; Fassnacht, M; Fragoso, MCBV; Giordano, R; Grisanti, S; Haak, HR; Hahner, S; Haissaguerre, M; Kastelan, D; Kimpel, O; Kroiss, M; Lacroix, A; Lasolle, H; Libé, R; Loli, P; Luconi, M; Megerle, F; Nölting, S; Perotti, P; Puglisi, S; Quinkler, M; Reimondo, G; Sormani, MP; Stigliano, A; Terzolo, M; Zatelli, MC, 2023)
"Central hypothyroidism was described previously in mitotane-treated patients but data on its prevalence and time of occurrence are limited."9.41Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline. ( Bourdeau, I; Caron, P; Godemel, S; Grunenwald, S; Lacroix, A; Le, XK; Mourot, A; Olney, HJ; Poirier, J, 2023)
"Mitotane is the only approved drug for treatment of adrenocortical carcinoma."9.17Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. ( Allolio, B; Baudin, E; Chadarevian, R; Fassnacht, M; Haak, HR; Kerkhofs, TM; Leboulleux, S; Mantero, F; Mueller, HH; Skogseid, B; Terzolo, M, 2013)
"The benefit-to-risk ratio of a high-dose strategy at the initiation of mitotane treatment of adrenocortical carcinoma (ACC) remains unknown."9.16High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. ( Al Ghuzlan, A; Baudin, E; Borget, I; Chanson, P; Deandreis, D; Drouard, L; Leboulleux, S; Mauclère-Denost, S; Paci, A; Schlumberger, M; Tabarin, A; Young, J, 2012)
"We designed a single-center retrospective study to assess the QT interval duration and to describe cardio vascular events among patients treated with mitotane for a adrenocortical carcinoma (ACC)."9.16No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma. ( Abbas, H; Bertagna, X; Chaderevian, R; Cohen, A; Dufaitre, G; Ederhy, S; Libé, R, 2012)
"Mitotane is the only adrenolytic drug approved by the Food and Drug Administration for treating adrenocortical carcinoma (ACC)."9.12Pharmacological profile and effects of mitotane in adrenocortical carcinoma. ( Acco, A; Bach, C; Bonatto, SJR; Corso, CR; de Figueiredo, BC; de Souza, LM, 2021)
"Mitotane is the only drug registered specifically for adrenocortical carcinoma."9.12How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives. ( Ettaieb, MHT; Haak, HR; Kerkhofs, TMA; Steenaard, RV, 2021)
"A previous Southwest Oncology Group study demonstrated a 30% response rate with the combination of cisplatin and mitotane in the treatment of patients with metastatic adrenocortical carcinoma."9.09Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. ( Baker, LH; Balcerzak, SP; Crawford, ED; Lew, D; Miller, GJ; Williamson, SK, 2000)
"The use of either mitotane or chemotherapy in the treatment of advanced adrenocortical carcinoma (ACC) has led to scanty and controversial results."9.08Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. ( Angeli, A; Berruti, A; Dogliotti, L; Pia, A; Terzolo, M, 1998)
"The adjuvant use of mitotane on adrenocortical carcinoma (ACC) has always been in controversy."8.98Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis. ( Liang, J; Liu, Z; Lu, Y; Tang, Y; Zhu, Y; Zou, Z, 2018)
"Description of novel findings about the mechanism of action of mitotane and its activity as an adjunctive postoperative measure, or for treatment of advanced adrenocortical carcinoma."8.90Practical treatment using mitotane for adrenocortical carcinoma. ( Allasino, B; De Francia, S; Terzolo, M; Zaggia, B, 2014)
"Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, (o,p'-DDD)] is the only drug approved for the treatment for adrenocortical carcinoma (ACC) and has also been used for various forms of glucocorticoid excess."8.87Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. ( Allolio, B; Fassnacht, M; Kroiss, M; Lutz, WK; Quinkler, M, 2011)
"Hypogonadism is common in male patients with adrenocortical carcinoma (ACC) who are under treatment with mitotane, but the phenomenon is underestimated, and its prevalence has been poorly studied."8.31Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study. ( Alberti, A; Berruti, A; Cappelli, C; Cosentini, D; Cremaschi, V; Delbarba, A; Facondo, P; Ferlin, A; Grisanti, S; Laganà, M; Pezzaioli, LC, 2023)
"Mitotane is a chiral drug used to treat adrenocortical carcinoma, being metabolized to the o,p'-dichlorodiphenyl acetic acid (o,p'-DDA), also a chiral compound."8.31Two-dimensional chromatography for enantiomeric analysis of mitotane and its metabolite o,p'-DDA in patients with adrenocortical carcinoma indicates enantioselective metabolism. ( Bach de Assis, C; Cavalcante de Figueiredo, B; Cruz Bonk, B; de Almeida Veiga, A; de Toledo Nogueira, B; Lada Degaut Pontes, F; Mera de Souza, L; Regina Rocha Martins, L; Rita Corso, C; Stadler, G, 2023)
" A 33-year-old woman who underwent surgery for adrenocortical carcinoma and treated with mitotane was referred for infertility."8.12Live birth after in-vitro maturation of oocytes in a patient with specific ovarian insufficiency caused by long-term mitotane treatment for adrenocortical carcinoma. ( Belin, F; Bry-Gauillard, H; Grynberg, M; Massin, N; Renoult-Pierre, P; Sifer, C; Vinolas, C; Young, J, 2022)
"Mitotane is the only approved drug for treating adrenocortical carcinoma (ACC)."8.12Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells. ( Abate, A; Berruti, A; Cosentini, D; Fiorentini, C; Grisanti, S; Grosso, E; Hantel, C; Laganà, M; Memo, M; Rossini, E; Scatolini, M; Sigala, S; Tamburello, M; Tiberio, GAM, 2022)
"Patients with adrenocortical carcinoma (ACC) are frequently on mitotane therapy for a long time period."8.12Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy. ( Al Ghuzlan, A; Baudin, E; Berruti, A; Cosentini, D; Deschamps, F; Frigerio, M; Gasparotti, R; Grisanti, S; Hadoux, J; Laganà, M; Lamartina, L; Libè, R; Maroldi, R; Pedersini, R; Terzolo, M; Valsecchi, C; Zamparini, M, 2022)
"Adjuvant treatment with mitotane and chemotherapy is recommended for paediatric advanced and metastatic adrenocortical carcinoma (ACC)."8.12Key factors for effective mitotane therapy in children with adrenocortical carcinoma. ( Brecht, I; Frühwald, MC; Kuhlen, M; Kunstreich, M; Lessel, L; Mier, P; Redlich, A; Schewe, DM; Schneider, D; Vorwerk, P, 2022)
"Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC)."8.02Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. ( Corssmit, EPM; Cusato, J; D'Avolio, A; Eekhoff, M; Ettaieb, MHT; Feelders, RA; Gelderblom, H; Guchelaar, HJ; Haak, HR; Kerkhofs, TMA; Kerstens, MN; Moes, DJAR; Swen, JJ; Timmers, HJLM; van der Straaten, RJHM; van Deun, L; Yin, A, 2021)
"Mitotane is used in the treatment of adrenocortical carcinoma (ACC)."8.02Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients. ( Andreassen, M; Daugaard, G; Krogh, J; Vikner, ME, 2021)
"This study presents an in vitro evaluation of the antitumor potential of a chitin-like exopolysaccharide (EPS, produced by Mortierella alpina) on Adrenocortical carcinoma cells (ACC) compared to mitotane, a commercial drug commonly used in ACC treatment, and known for its side effects."8.02In vitro cytotoxic effect of a chitin-like polysaccharide produced by Mortierella alpina on adrenocortical carcinoma cells H295R, and its use as mitotane adjuvant. ( Bonatto, SJR; de Carvalho, JC; Goyzueta Mamani, LD; Soccol, CR; Tanobe, VAO, 2021)
"European and French guidelines for ENSAT stage IV low tumor burden or indolent adrenocortical carcinoma (ACC) recommend a combination of mitotane and locoregional treatments (LRT) as first-line treatment."8.02Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma. ( Al Ghuzlan, A; Baudin, E; Boilève, A; de Baere, T; Deschamps, F; Faron, M; Hadoux, J; Hescot, S; Lamartina, L; Leboulleux, S; Mathy, E; Roux, C; Tselikas, L, 2021)
"Patients with adrenocortical carcinoma (ACC) often fail mitotane treatment and deal with severe toxicity, marking the relevance of predictive parameters for treatment outcome."7.96The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures. ( Creemers, SG; de Herder, WW; Dogan, F; Feelders, RA; Franssen, GJH; Hofland, LJ; van Koetsveld, PM, 2020)
"Mitotane is an adrenolytic drug that is used as an adjuvant to treat adrenocortical carcinoma."7.96Ovarian cyst formation in women of reproductive age receiving mitotane as part of the treatment of adrenocortical carcinoma: Clinical and experimental observations. ( Abrahamsson, G; Ahlman, H; Ekerhovd, E; Janson, PO; Jansson, S; Norström, A; Wängberg, B, 2020)
"Objective response rate to mitotane in advanced adrenocortical carcinoma (ACC) is approximately 20%, and adverse drug effects are frequent."7.96Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. ( Altieri, B; Basile, V; Berruti, A; Canu, L; Della Casa, S; Fassnacht, M; Fragoso, MCBV; Kircher, S; Kroiss, M; Lacombe, AMF; Landwehr, LS; Megerle, F; Paiva, I; Ronchi, CL; Sbiera, S; Schreiner, J; Terzolo, M; Volante, M; Weigand, I; Zerbini, MCN, 2020)
" Mitotane therapy of adrenocortical carcinoma (ACC) has been shown to act through lipid-induced ER-stress."7.91Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane. ( Fassnacht, M; Kendl, S; Kroiss, M; Sbiera, I; Sbiera, S; Weigand, I, 2019)
"Mitotane (also termed o,p'‑DDD) is the most effective therapy for advanced adrenocortical carcinoma (ACC)."7.91Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management. ( Amazit, L; Baudin, E; Boulate, G; Hescot, S; Lombes, A; Lombes, M; Naman, A; Paci, A; Pussard, E; Seck, A, 2019)
"Although mitotane is the only approved drug for the treatment of adrenocortical carcinoma (ACC), data on monotherapy in advanced disease are still scarce."7.88Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. ( Beuschlein, F; Fassnacht, M; Hahner, S; Herrmann, W; Kroiss, M; Megerle, F; Pulzer, A; Quinkler, M; Ronchi, CL; Schloetelburg, W, 2018)
" Recent studies have shown that an important component in the mechanism of action of mitotane, the only approved drug for the medical treatment of adrenocortical carcinoma (ACC), is represented by activation of ER stress through inhibition of the SOAT1 enzyme and accumulation of toxic lipids."7.88The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways. ( Benhida, R; Doghman-Bouguerra, M; Lalli, E; Rocchi, S; Ronco, C; Ruggiero, C, 2018)
"Mitotane is the reference drug for adrenocortical carcinoma (ACC) and the metabolic activation of the drug is considered as essential for its activity."7.88CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. ( Berruti, A; De Francia, S; Germano, A; Perotti, P; Rapa, I; Saba, L; Terzolo, M; Volante, M, 2018)
"Mitotane is used for the treatment of adrenocortical carcinoma."7.88Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients. ( Arshad, U; Fassnacht, M; Frechen, S; Fuhr, U; Hamacher, S; Herterich, S; Kroiss, M; Kurlbaum, M; Megerle, F; Taubert, M, 2018)
"In 2007, a retrospective case-control study provided evidence that adjuvant mitotane prolongs recurrence-free survival (RFS) in patients with radically resected adrenocortical carcinoma (ACC)."7.85Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. ( Arvat, E; Berruti, A; Boscaro, M; Claps, M; Daffara, F; Fassnacht, M; Grisanti, S; Hahner, S; Loli, P; Mannelli, M; Porpiglia, F; Pulzer, A; Terzolo, M; Tiberio, G; Volante, M; Zaggia, B, 2017)
" The present in-vitro study shows that AMG 900 inhibits aurora kinases in adrenocortical carcinoma cells."7.85The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line. ( Andrade, AF; Antonini, SRR; Borges, KS; Marco Antonio, DS; Scrideli, CA; Silveira, VS; Tone, LG; Vasconcelos, EJR, 2017)
"Mitotane is the reference drug for the adrenocortical carcinoma treatment; its pharmacological activity seems to depend on drug transformation in two active metabolites: o,p'-DDE (dichlorodiphenylethene) and o,p'-DDA (dichlorodiphenylacetate)."7.85Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. ( Allegra, S; Berruti, A; Carrella, S; Cusato, J; D'Avolio, A; Daffara, FC; De Francia, S; De Martino, F; Di Carlo, F; Ferrero, A; Piccione, FM; Pirro, E; Tampellini, M; Terzolo, M, 2017)
"Oral mitotane (o,p'-DDD) is a cornerstone of medical treatment for adrenocortical carcinoma (ACC)."7.83Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. ( Fassnacht, M; Heinz, W; Kendl, S; Klinker, H; Kroiss, M; Lapa, C; Plonné, D; Ronchi, CL; Sbiera, S; Schirbel, A; Schirmer, D; Zink, M, 2016)
"Current treatment guidelines recommend adjuvant mitotane after resection of adrenocortical carcinoma with high-risk features (eg, tumor rupture, positive margins, positive lymph nodes, high grade, elevated mitotic index, and advanced stage)."7.83Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. ( Duh, QY; Ethun, CG; Fields, RC; Gad, S; Glenn, J; Hatzaras, I; Jin, LX; Keplinger, K; Kiernan, CM; Levine, EA; Maithel, SK; Mansour, JC; Pawlik, TM; Phay, JE; Postlewait, LM; Poultsides, GA; Prescott, JD; Salem, A; Seiser, N; Shenoy, R; Sicklick, JK; Solorzano, CC; Staley, CA; Tran, TB; Votanopoulos, KI; Wang, TS; Weber, SM; Yopp, AC, 2016)
"Mitotane has been used for more than 5 decades as therapy for adrenocortical carcinoma (ACC)."7.83Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature. ( Bourdeau, I; Cohade, C; El Ghorayeb, N; Lacroix, A; Latour, M; Mazzuco, TL; Olney, H; Perrotte, P; Rondeau, G; Sabourin, A, 2016)
"Evaluation of patient characteristics and mitotane use in the treatment of adrenocortical carcinoma (ACC) over a 4-year period in Belgium."7.83Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients. ( Banh, C; Bex, M; Chadarevian, R; Gil, T; Maiter, D; T'Sjoen, G; Vroonen, L, 2016)
"Mitotane is the only drug approved for treatment of the orphan disease adrenocortical carcinoma (ACC) and was recently shown to be the first clinically used drug acting through endoplasmic reticulum (ER)-stress induced by toxic lipids."7.83Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. ( Fassnacht, M; Kendl, S; Kroiss, M; Kurlbaum, M; Sbiera, S, 2016)
"Mitotane is the drug of choice in medical treatment of adrenocortical carcinoma."7.81Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma. ( den Hartigh, J; Derijks, LJ; Ettaieb, H; Gelderblom, H; Guchelaar, HJ; Haak, HR; Kerkhofs, TM; Neef, K, 2015)
"Mitotane is an adrenolytic and anticortisolic drug used in adrenocortical carcinoma (ACC), Cushing's disease (CD), and ectopic ACTH syndrome."7.81Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease. ( Bachelot, A; Baudin, E; Bernard, V; Bry-Gauillard, H; Chanson, P; Crinière, L; Do Cao, C; Droumaguet, C; Guignat, L; Leboulleux, S; Maiter, D; Pierre, P; Salenave, S; Santulli, P; Schlumberger, M; Touraine, P; Young, J, 2015)
"Mitotane (o,p'-DDD), the only approved drug for advanced adrenocortical carcinoma (ACC), is a lipophilic agent that accumulates into circulating lipoprotein fractions and high-lipid-containing tissues."7.81Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma. ( Baudin, E; Broutin, S; Cockenpot, F; Guerin, M; Hescot, S; Huby, T; Lombès, M; Paci, A; Seck, A; Young, J, 2015)
"Mitotane (o,p'DDD) is the most effective treatment of advanced adrenocortical carcinoma (ACC) but its mechanism of action remains unknown."7.80The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment. ( Al Ghuzlan, A; Baudin, E; Brailly-Tabard, S; Hescot, S; Lombès, M; Paci, A; Seck, A; Slama, A; Trabado, S; Viengchareun, S; Young, J, 2014)
"Mitotane is currently employed as adjuvant therapy as well as in the medical treatment of adrenocortical carcinoma (ACC), alone or in combination with chemotherapeutic agents."7.80Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells. ( Benfini, K; Di Pasquale, C; Falletta, S; Feo, C; Gagliano, T; Gentilin, E; Tagliati, F; Tassinari, M; Uberti, ED; Zatelli, MC, 2014)
"We herein report a case of marked transient hypercholesterolemia in a man receiving low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma."7.80Marked transient hypercholesterolemia caused by low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma. ( Inazu, A; Kawashiri, MA; Mabuchi, H; Nohara, A; Tada, H; Yamagishi, M, 2014)
"Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC)."7.79Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. ( Al Ghuzlan, A; Allolio, B; Ardito, A; Baudin, AE; Berruti, A; Daffara, F; De Francia, S; deVries, JH; Fassnacht, M; Feelders, RA; Haak, HR; Kroiss, M; Leboulleux, S; Perotti, P; Terzolo, M; Volante, M; Zaggia, B, 2013)
"Mitotane is a widely used drug in the therapy of adrenocortical carcinoma (ACC)."7.79Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma. ( Doghman, M; Lalli, E, 2013)
"In patients with adrenocortical carcinoma (ACC) mitotane activity has been suggested to depend on plasma levels 14 mg/liter or greater and metabolite formation."7.77Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. ( Allolio, B; Baudin, E; Berruti, A; Chadarevian, R; Daffara, F; den Hartigh, J; Fassnacht, M; Haak, HR; Hermsen, IG; Houterman, S; Leboulleux, S; Schlumberger, M; Terzolo, M, 2011)
"We present the case of a female patient with virilising adrenocortical carcinoma treated surgically who conceived during adjuvant treatment with mitotane."7.77Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report. ( Baszko-Błaszyk, D; Ochmańska, K; Sowiński, J; Waśko, R, 2011)
"Mitotane treatment in adrenocortical carcinoma (ACC) results in unreliable measurement of serum total cortisol (TC) levels because of an elevation in corticosteroid-binding globulin (CBG)."7.76Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. ( Ajodha, S; Akker, SA; Alexandraki, KI; Allolio, B; Christ-Crain, M; Drake, WM; Edwards, R; Fassnacht, M; Grossman, AB; Kaltsas, GA; le Roux, CW, 2010)
"To progress in the stratification of the first-line therapeutic management of metastatic adrenocortical carcinoma (ACC), we searched for prognostic parameters of survival in patients treated with combined mitotane- and cisplatinum-based chemotherapy as first-line."7.76Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. ( Al Ghuzlan, A; Baudin, E; Caillou, B; Castaing, M; Chanson, P; de Baere, T; Dromain, C; Elias, D; Leboulleux, S; Malandrino, P; Paci, A; Schlumberger, M; Travagli, JP; Young, J, 2010)
"A 57-year-old white woman with metastases to lungs and liver from virilizing adrenocortical carcinoma (ACC) was treated with radical nephroadrenalectomy followed by oral mitotane 3 to 6 g/day for 5 months."7.75Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy. ( Banerjee, TK; Chalasani, S; McKenzie, AK; Vats, HS, 2009)
"Adjuvant mitotane may prolong recurrence-free survival in patients with radically resected adrenocortical carcinoma."7.74Adjuvant mitotane treatment for adrenocortical carcinoma. ( Allolio, B; Ambrosi, B; Angeli, A; Arvat, E; Berruti, A; Bollito, E; Bruzzi, P; Buci, L; Conton, PA; Daffara, F; Dogliotti, L; Fassnacht, M; Grossrubatscher, E; Hahner, S; Koschker, AC; Loli, P; Lombardi, G; Mannelli, M; Mantero, F; Papotti, M; Reimondo, G; Rossetto, R; Saeger, W; Sperone, P; Tauchmanova, L; Terzolo, M, 2007)
"Mitotane is considered to be the drug of choice for patients with inoperable, recurrent and metastatic adrenocortical carcinoma, although a favourable effect of this drug on survival has never been documented."7.69Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. ( Fleuren, GJ; Goslings, BM; Haak, HR; Hermans, J; Krans, HM; Lentjes, EG; van de Velde, CJ, 1994)
"Cabazitaxel has a manageable toxicity profile but is poorly active as second/third-line treatment in advanced ACC patients."7.11Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma. ( Abate, A; Ambrosini, R; Berruti, A; Canu, L; Cosentini, D; Ferrari, VD; Gianoncelli, A; Grisanti, S; Laganà, M; Sigala, S; Terzolo, M; Tiberio, GAM; Turla, A; Zamparini, M, 2022)
" IMC-A12 was dosed at 10 mg/kg intravenously every 2 weeks."6.79The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. ( Agamah, E; Else, T; Hammer, GD; Hasseltine, EA; Hesseltine, EA; Lerario, AM; Ramm, CA; Rao, K; Shah, MH; Stadler, WM; Worden, FP, 2014)
"Mitotane plasma levels were determined using high-performance liquid chromatography."6.72Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. ( Callefe, LG; Ferman, S; Figueiredo, BC; Lichtvan, LL; Oliveira, BH; Parise, GA; Pianovski, MA; Piovezan, GC; Santana, MH; Stinghen, ST; Voss, SZ; Zancanella, P, 2006)
"Mitotane was stopped at gestation week 6."6.49Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature. ( Blumenfeld, Z; Bronshtein, M; Jaffe, A; Salmon, A; Tripto-Shkolnik, L, 2013)
"His aldosterone/renin ratio was high and plasma renin activity was low."5.91[A Case of Aldosterone-Producing Adrenocortical Carcinoma]. ( Asai, S; Hashimoto, K; Ishihara, M; Kanamaru, S; Katsushima, H; Nakayasu, R; Oshiro, H; Shimizu, Y; Son, C; Tsuji, K; Utsunomiya, N, 2023)
"Mitotane TR was significantly reduced in the SPL group, as was time-in-range to progression."5.72Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients. ( Haberbosch, L; Jumpertz von Schwartzenberg, R; Mai, K; Maurer, L; Sandforth, A; Spranger, J; Wernicke, C, 2022)
"The pathological diagnosis was adrenocortical carcinoma with negative surgical margin."5.72[A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission]. ( Iinuma, K; Kato, D; Kawase, K; Kawase, M; Koie, T; Miyazaki, T; Nakai, C; Nakane, K; Namiki, S; Takai, M; Takeuchi, S; Takeuchi, Y; Tsuchiya, T; Ueda, S, 2022)
"At metastatic stage, treatment of adrenocortical carcinoma (ACC) relies in first line on mitotane therapy, combination of mitotane with locoregional therapies or cisplatin-based chemotherapy according to initial presentation."5.69Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE. ( Baudin, E; de la Fouchardiere, C; Debien, V; Do Cao, C; Drui, D; du Rusquec, P; Hadoux, J; Haissaguerre, M; Hescot, S; Le Tourneau, C; Libé, R; Massard, C; Vezzosi, D, 2023)
"Adjuvant treatment with mitotane is commonly used after resection of adrenocortical carcinoma; however, treatment remains controversial, particularly if risk of recurrence is not high."5.69Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study. ( Arlt, W; Bancos, I; Basile, V; Baudin, E; Berchialla, P; Berruti, A; Bertherat, J; Beuschlein, F; Bourdeau, I; Bovis, F; Bruzzi, P; Canu, L; Caron, P; Chabre, O; Chortis, V; Cosentini, D; Decoudier, B; Dusek, T; Ettaieb, MH; Fassnacht, M; Fragoso, MCBV; Giordano, R; Grisanti, S; Haak, HR; Hahner, S; Haissaguerre, M; Kastelan, D; Kimpel, O; Kroiss, M; Lacroix, A; Lasolle, H; Libé, R; Loli, P; Luconi, M; Megerle, F; Nölting, S; Perotti, P; Puglisi, S; Quinkler, M; Reimondo, G; Sormani, MP; Stigliano, A; Terzolo, M; Zatelli, MC, 2023)
"Mitotane was administered to 2 patients as an adjuvant therapy and to 8 patients for systemic control."5.62Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma. ( Fukuda, N; Hayashi, N; Inamura, K; Komai, Y; Nakano, K; Numao, N; Ohmoto, A; Ono, M; Sato, Y; Shigematsu, Y; Takahashi, S; Tomomatsu, J; Urasaki, T; Wang, X; Yonese, J; Yuasa, T; Yunokawa, M, 2021)
"Mitotane, the standard treatment for ACC, impairs adrenocortical steroid biosynthesis and cholesterol metabolism."5.56Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma. ( Basile, V; Biasi, F; Caccia, C; Germano, A; Iaia, N; Leoni, V; Poli, G; Puglisi, S; Rossin, D; Saba, L; Terzolo, M, 2020)
"Under the diagnosis of stage IV adrenocortical carcinoma, mitotane therapy was started in May 2013."5.51[A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP]. ( Hanai, T; Nakayama, T; Onuki, T; Suzuki, K; Yamashita, D, 2019)
"Mitotane effect was explored stratifying patients by staging (stage I-II vs stage III), hormone secretion (yes vs no) and Ki67 index."5.51Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. ( Basile, V; Berchialla, P; Berruti, A; Calabrese, A; Perotti, P; Pia, A; Porpiglia, F; Puglisi, S; Reimondo, G; Saba, L; Terzolo, M; Veltri, A; Volante, M, 2019)
"Adrenal insufficiency is common with mitotane use and aggressive treatment with steroid supplementation should be considered when appropriate to avoid excess toxicities."5.46Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug. ( Chou, J; Gerst, S; Gopalan, A; Hrabovsky, A; Kampel, L; Katz, S; Kelly, C; Lung, B; Raj, N; Reidy-Lagunes, DL; Saltz, LB; Untch, BR, 2017)
"Adrenocortical carcinoma is a rare tumour with high malignancy and poor prognosis."5.46Use of a levonorgestrel-releasing intrauterine device for menorrhagia treatment during adjuvant therapy of adrenocortical carcinoma with mitotane. ( Czuczwar, P; Paszkowski, T; Szkodziak, F; Szkodziak, PR; Woźniak, S, 2017)
"Central hypothyroidism was described previously in mitotane-treated patients but data on its prevalence and time of occurrence are limited."5.41Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline. ( Bourdeau, I; Caron, P; Godemel, S; Grunenwald, S; Lacroix, A; Le, XK; Mourot, A; Olney, HJ; Poirier, J, 2023)
"We aimed at investigating in vitro the cytotoxic activity (determined using WST-1, apoptosis and cell cycle assays) of gemcitabine, alone or in combination with mitotane, in mitotane-sensitive H295R and mitotane-insensitive SW-13 cells."5.40Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. ( Berruti, A; Carturan, S; Germano, A; Lo Buono, N; Papotti, M; Rapa, I; Terzolo, M; Volante, M, 2014)
"The pregnancy was complicated by fetal exposure to mitotane and dexamethasone."5.37Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure. ( Burym, C; Cronin, CM; Kojori, F; Salamon, E; Sellers, EA, 2011)
"A 58-year-old man had adrenocortical carcinoma in the right adrenal gland."5.30Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. ( Demura, H; Hirohara, D; Kanazawa, M; Nomura, K; Sawada, T; Seki, M; Takasaki, K, 1999)
"The management of patients with advanced/metastatic adrenocortical carcinoma (ACC) is challenging, EDP-M (etoposide, doxorubicin, cisplatin combined with mitotane) is the standard regimen."5.22Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen. ( Abate, A; Berruti, A; Consoli, F; Cosentini, D; Cremaschi, V; Ferrari, VD; Grisanti, S; Laganà, M; Sigala, S; Turla, A, 2022)
"Surgery, followed or not by adjuvant mitotane, is the current mainstay of therapy for patients with early-stage adrenocortical carcinoma (ACC)."5.22Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art? ( Abate, A; Berruti, A; Cosentini, D; Cremaschi, V; Grisanti, S; Laganà, M; Rossini, E; Sigala, S; Tamburello, M; Turla, A, 2022)
"Mitotane is the drug of choice in patients with adrenocortical carcinoma."5.19Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring. ( den Hartigh, J; Derijks, LJ; Eekhoff, EM; Ettaieb, MH; Gelderblom, H; Guchelaar, HJ; Haak, HR; Kerkhofs, TM; Neef, C, 2014)
"Mitotane is the only approved drug for treatment of adrenocortical carcinoma."5.17Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma. ( Allolio, B; Baudin, E; Chadarevian, R; Fassnacht, M; Haak, HR; Kerkhofs, TM; Leboulleux, S; Mantero, F; Mueller, HH; Skogseid, B; Terzolo, M, 2013)
"Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane] is the first-line treatment for metastatic adrenocortical carcinoma (ACC) and is also regularly used in the adjuvant setting after presumed complete removal of the primary tumor."5.17Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. ( Allolio, B; Arlt, W; Bertagna, X; Bertherat, J; Beuschlein, F; Chortis, V; Fassnacht, M; Hahner, S; Hughes, BA; Karavitaki, N; Libé, R; Mannelli, M; Mantero, F; Nightingale, P; O'Neil, DM; Opocher, G; Porfiri, E; Quinkler, M; Schneider, P; Shackleton, CH; Sherlock, M; Stewart, PM; Taylor, AE; Terzolo, M; Tomlinson, JW, 2013)
"The benefit-to-risk ratio of a high-dose strategy at the initiation of mitotane treatment of adrenocortical carcinoma (ACC) remains unknown."5.16High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. ( Al Ghuzlan, A; Baudin, E; Borget, I; Chanson, P; Deandreis, D; Drouard, L; Leboulleux, S; Mauclère-Denost, S; Paci, A; Schlumberger, M; Tabarin, A; Young, J, 2012)
"We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg per square meter on day 1), and cisplatin (40 mg per square meter on days 3 and 4) (EDP) every 4 weeks or streptozocin (streptozotocin) (1 g on days 1 to 5 in cycle 1; 2 g on day 1 in subsequent cycles) every 3 weeks."5.16Combination chemotherapy in advanced adrenocortical carcinoma. ( Allolio, B; Arlt, W; Baudin, E; Berruti, A; Beuschlein, F; de la Fouchardière, C; Edgerly, M; Fassnacht, M; Fojo, T; Gelderblom, H; Haak, H; Hahner, S; Hermsen, I; Jarzab, B; Kenn, W; Kroiss, M; Lacroix, A; Leboulleux, S; Mantero, F; Müller, HH; Quinkler, M; Schade-Brittinger, C; Schlumberger, M; Schteingart, DE; Sender, M; Skogseid, B; Sorbye, H; Sperone, P; Stepan, V; Sundin, A; Tabarin, A; Terzolo, M; Torpy, DJ; Weismann, D; Welin, S; Willenberg, HS; Wilmink, H, 2012)
"We designed a single-center retrospective study to assess the QT interval duration and to describe cardio vascular events among patients treated with mitotane for a adrenocortical carcinoma (ACC)."5.16No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma. ( Abbas, H; Bertagna, X; Chaderevian, R; Cohen, A; Dufaitre, G; Ederhy, S; Libé, R, 2012)
" Both patients were diagnosed with adrenocortical carcinoma (ACC) and were exposed to mitotane."5.15Mitotane has a strong and a durable inducing effect on CYP3A4 activity. ( Gelderblom, H; Guchelaar, HJ; Hartigh, Jd; Ploeger, BA; Romijn, JA; van Erp, NP, 2011)
"A recent nonrandomized interinstitutional study reported that adjuvant mitotane following surgery for adrenocortical carcinoma (ACC) was associated with decreased recurrence."5.14Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. ( Callender, GG; Evans, DB; Grubbs, EG; Lee, JE; Perrier, ND; Phan, AT; Xing, Y, 2010)
"Mitotane is the only adrenolytic drug approved by the Food and Drug Administration for treating adrenocortical carcinoma (ACC)."5.12Pharmacological profile and effects of mitotane in adrenocortical carcinoma. ( Acco, A; Bach, C; Bonatto, SJR; Corso, CR; de Figueiredo, BC; de Souza, LM, 2021)
"Mitotane is the only drug registered specifically for adrenocortical carcinoma."5.12How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives. ( Ettaieb, MHT; Haak, HR; Kerkhofs, TMA; Steenaard, RV, 2021)
"Mitotane as tablet form is currently the standard treatment for adrenocortical carcinoma."5.12The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging. ( Ahmad, T; Groll, J; Haider, MS; Kroiss, M; Luxenhofer, R; Scherf-Clavel, O, 2021)
"A previous Southwest Oncology Group study demonstrated a 30% response rate with the combination of cisplatin and mitotane in the treatment of patients with metastatic adrenocortical carcinoma."5.09Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. ( Baker, LH; Balcerzak, SP; Crawford, ED; Lew, D; Miller, GJ; Williamson, SK, 2000)
"The use of either mitotane or chemotherapy in the treatment of advanced adrenocortical carcinoma (ACC) has led to scanty and controversial results."5.08Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. ( Angeli, A; Berruti, A; Dogliotti, L; Pia, A; Terzolo, M, 1998)
"Almost one decade ago, etoposide, doxorubicin, cisplatin and mitotane (EDP-M) has been established as first-line systemic therapy of metastatic adrenocortical carcinoma (ACC)."5.05Next-generation therapies for adrenocortical carcinoma. ( Altieri, B; Fassnacht, M; Kroiss, M; Ronchi, CL, 2020)
"The adjuvant use of mitotane on adrenocortical carcinoma (ACC) has always been in controversy."4.98Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis. ( Liang, J; Liu, Z; Lu, Y; Tang, Y; Zhu, Y; Zou, Z, 2018)
"Description of novel findings about the mechanism of action of mitotane and its activity as an adjunctive postoperative measure, or for treatment of advanced adrenocortical carcinoma."4.90Practical treatment using mitotane for adrenocortical carcinoma. ( Allasino, B; De Francia, S; Terzolo, M; Zaggia, B, 2014)
"Mitotane [1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane, (o,p'-DDD)] is the only drug approved for the treatment for adrenocortical carcinoma (ACC) and has also been used for various forms of glucocorticoid excess."4.87Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. ( Allolio, B; Fassnacht, M; Kroiss, M; Lutz, WK; Quinkler, M, 2011)
"Mitotane has been used for 50 years as the first-line drug in the treatment of disseminated adrenocortical carcinoma."4.86[Mitotane in the treatment of adrenal carcinoma]. ( Sane, T, 2010)
"A retrospective analysis showing that adjuvant mitotane may prolong recurrence-free survival in a large cohort of patients with radically resected adrenocortical carcinoma has recently been published."4.84Adjunctive treatment of adrenocortical carcinoma. ( Berruti, A; Terzolo, M, 2008)
"Treatment for advanced adrenocortical carcinoma (ACC) consists of mitotane alone or combined with etoposide, doxorubicin, and cisplatin (EDP)."4.31Inflammation-based scores as predictors of treatment response in advanced adrenocortical carcinoma. ( Abbas, H; Altieri, B; Asia, M; Detomas, M; Elhassan, YS; Mangone, A; Mantovani, G; Prete, A; Ronchi, CL, 2023)
"Hypogonadism is common in male patients with adrenocortical carcinoma (ACC) who are under treatment with mitotane, but the phenomenon is underestimated, and its prevalence has been poorly studied."4.31Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study. ( Alberti, A; Berruti, A; Cappelli, C; Cosentini, D; Cremaschi, V; Delbarba, A; Facondo, P; Ferlin, A; Grisanti, S; Laganà, M; Pezzaioli, LC, 2023)
" Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine malignancy for which mitotane (MTT) treatment represents the first-line therapy, though its efficacy is limited to a therapeutic window level (14-20 mg/L)."4.31Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane. ( Amedei, A; Baldi, S; Cantini, G; Canu, L; Di Gloria, L; Fei, L; Luconi, M; Nannini, G; Nesi, G; Niccolai, E; Propato, AP; Puglisi, S; Ramazzotti, M, 2023)
"Mitotane is a chiral drug used to treat adrenocortical carcinoma, being metabolized to the o,p'-dichlorodiphenyl acetic acid (o,p'-DDA), also a chiral compound."4.31Two-dimensional chromatography for enantiomeric analysis of mitotane and its metabolite o,p'-DDA in patients with adrenocortical carcinoma indicates enantioselective metabolism. ( Bach de Assis, C; Cavalcante de Figueiredo, B; Cruz Bonk, B; de Almeida Veiga, A; de Toledo Nogueira, B; Lada Degaut Pontes, F; Mera de Souza, L; Regina Rocha Martins, L; Rita Corso, C; Stadler, G, 2023)
" A 33-year-old woman who underwent surgery for adrenocortical carcinoma and treated with mitotane was referred for infertility."4.12Live birth after in-vitro maturation of oocytes in a patient with specific ovarian insufficiency caused by long-term mitotane treatment for adrenocortical carcinoma. ( Belin, F; Bry-Gauillard, H; Grynberg, M; Massin, N; Renoult-Pierre, P; Sifer, C; Vinolas, C; Young, J, 2022)
"Mitotane is the only approved drug for treating adrenocortical carcinoma (ACC)."4.12Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells. ( Abate, A; Berruti, A; Cosentini, D; Fiorentini, C; Grisanti, S; Grosso, E; Hantel, C; Laganà, M; Memo, M; Rossini, E; Scatolini, M; Sigala, S; Tamburello, M; Tiberio, GAM, 2022)
"Patients with adrenocortical carcinoma (ACC) are frequently on mitotane therapy for a long time period."4.12Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy. ( Al Ghuzlan, A; Baudin, E; Berruti, A; Cosentini, D; Deschamps, F; Frigerio, M; Gasparotti, R; Grisanti, S; Hadoux, J; Laganà, M; Lamartina, L; Libè, R; Maroldi, R; Pedersini, R; Terzolo, M; Valsecchi, C; Zamparini, M, 2022)
"Adjuvant treatment with mitotane and chemotherapy is recommended for paediatric advanced and metastatic adrenocortical carcinoma (ACC)."4.12Key factors for effective mitotane therapy in children with adrenocortical carcinoma. ( Brecht, I; Frühwald, MC; Kuhlen, M; Kunstreich, M; Lessel, L; Mier, P; Redlich, A; Schewe, DM; Schneider, D; Vorwerk, P, 2022)
"Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC)."4.02Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing. ( Corssmit, EPM; Cusato, J; D'Avolio, A; Eekhoff, M; Ettaieb, MHT; Feelders, RA; Gelderblom, H; Guchelaar, HJ; Haak, HR; Kerkhofs, TMA; Kerstens, MN; Moes, DJAR; Swen, JJ; Timmers, HJLM; van der Straaten, RJHM; van Deun, L; Yin, A, 2021)
"Mitotane is used in the treatment of adrenocortical carcinoma (ACC)."4.02Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients. ( Andreassen, M; Daugaard, G; Krogh, J; Vikner, ME, 2021)
"Following initial surgery, patients with adrenocortical carcinoma (ACC) are commonly treated with the adrenolytic substance mitotane in an adjuvant or therapeutic setting."4.02Predicitve Value of FDG Uptake in the Remaining Adrenal Gland Following Adrenalectomy for Adrenocortical Cancer. ( Beuschlein, F; Bluemel, C; Fassnacht, M; Hahner, S; Loewe, R; Pfluger, T; Reincke, M; Rogowski-Lehmann, N, 2021)
"European and French guidelines for ENSAT stage IV low tumor burden or indolent adrenocortical carcinoma (ACC) recommend a combination of mitotane and locoregional treatments (LRT) as first-line treatment."4.02Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma. ( Al Ghuzlan, A; Baudin, E; Boilève, A; de Baere, T; Deschamps, F; Faron, M; Hadoux, J; Hescot, S; Lamartina, L; Leboulleux, S; Mathy, E; Roux, C; Tselikas, L, 2021)
"Patients with adrenocortical carcinoma (ACC) often fail mitotane treatment and deal with severe toxicity, marking the relevance of predictive parameters for treatment outcome."3.96The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures. ( Creemers, SG; de Herder, WW; Dogan, F; Feelders, RA; Franssen, GJH; Hofland, LJ; van Koetsveld, PM, 2020)
"Mitotane is an adrenolytic drug that is used as an adjuvant to treat adrenocortical carcinoma."3.96Ovarian cyst formation in women of reproductive age receiving mitotane as part of the treatment of adrenocortical carcinoma: Clinical and experimental observations. ( Abrahamsson, G; Ahlman, H; Ekerhovd, E; Janson, PO; Jansson, S; Norström, A; Wängberg, B, 2020)
"Objective response rate to mitotane in advanced adrenocortical carcinoma (ACC) is approximately 20%, and adverse drug effects are frequent."3.96Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study. ( Altieri, B; Basile, V; Berruti, A; Canu, L; Della Casa, S; Fassnacht, M; Fragoso, MCBV; Kircher, S; Kroiss, M; Lacombe, AMF; Landwehr, LS; Megerle, F; Paiva, I; Ronchi, CL; Sbiera, S; Schreiner, J; Terzolo, M; Volante, M; Weigand, I; Zerbini, MCN, 2020)
"Mitotane causes hypercholesterolemia in patients with adrenocortical carcinoma (ACC)."3.96Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth. ( Avena, P; Barile, SN; Casaburi, I; Chimento, A; De Luca, A; Fallo, F; Lasorsa, FM; Lerario, AM; Malivindi, R; Nocito, MC; Palmieri, L; Pezzani, R; Pezzi, V; Pilon, C; Rago, V; Sculco, S; Sirianni, R; Trotta, F, 2020)
"Low-dose mitotane has been widely used for many decades in patients with advanced adrenocortical carcinoma (ACC), which exhibited good safety profiles compared with the high-dose regimen."3.96A case report of neurological adverse events caused by short-term and low-dose treatment of mitotane: The role of therapeutic drug monitoring. ( Deng, JH; Fu, Q; Liu, X; Mei, D; Tang, Y; Zhang, B, 2020)
" Mitotane therapy of adrenocortical carcinoma (ACC) has been shown to act through lipid-induced ER-stress."3.91Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane. ( Fassnacht, M; Kendl, S; Kroiss, M; Sbiera, I; Sbiera, S; Weigand, I, 2019)
"Mitotane (also termed o,p'‑DDD) is the most effective therapy for advanced adrenocortical carcinoma (ACC)."3.91Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management. ( Amazit, L; Baudin, E; Boulate, G; Hescot, S; Lombes, A; Lombes, M; Naman, A; Paci, A; Pussard, E; Seck, A, 2019)
"Although mitotane is the only approved drug for the treatment of adrenocortical carcinoma (ACC), data on monotherapy in advanced disease are still scarce."3.88Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. ( Beuschlein, F; Fassnacht, M; Hahner, S; Herrmann, W; Kroiss, M; Megerle, F; Pulzer, A; Quinkler, M; Ronchi, CL; Schloetelburg, W, 2018)
" Recent studies have shown that an important component in the mechanism of action of mitotane, the only approved drug for the medical treatment of adrenocortical carcinoma (ACC), is represented by activation of ER stress through inhibition of the SOAT1 enzyme and accumulation of toxic lipids."3.88The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways. ( Benhida, R; Doghman-Bouguerra, M; Lalli, E; Rocchi, S; Ronco, C; Ruggiero, C, 2018)
"Mitotane is the reference drug for adrenocortical carcinoma (ACC) and the metabolic activation of the drug is considered as essential for its activity."3.88CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells. ( Berruti, A; De Francia, S; Germano, A; Perotti, P; Rapa, I; Saba, L; Terzolo, M; Volante, M, 2018)
"Mitotane is used for the treatment of adrenocortical carcinoma."3.88Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients. ( Arshad, U; Fassnacht, M; Frechen, S; Fuhr, U; Hamacher, S; Herterich, S; Kroiss, M; Kurlbaum, M; Megerle, F; Taubert, M, 2018)
"Mitotane is a cytostatic antineoplastic agent that is used in the treatment of adrenocortical carcinoma and Cushing's syndrome."3.88Mitotane-induced dyspnoea: an unusual side effect. ( Adhikari, S; Amjad, W; Farooq, AU; Kochar, T, 2018)
"In 2007, a retrospective case-control study provided evidence that adjuvant mitotane prolongs recurrence-free survival (RFS) in patients with radically resected adrenocortical carcinoma (ACC)."3.85Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma. ( Arvat, E; Berruti, A; Boscaro, M; Claps, M; Daffara, F; Fassnacht, M; Grisanti, S; Hahner, S; Loli, P; Mannelli, M; Porpiglia, F; Pulzer, A; Terzolo, M; Tiberio, G; Volante, M; Zaggia, B, 2017)
" The present in-vitro study shows that AMG 900 inhibits aurora kinases in adrenocortical carcinoma cells."3.85The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line. ( Andrade, AF; Antonini, SRR; Borges, KS; Marco Antonio, DS; Scrideli, CA; Silveira, VS; Tone, LG; Vasconcelos, EJR, 2017)
"Mitotane is the reference drug for the adrenocortical carcinoma treatment; its pharmacological activity seems to depend on drug transformation in two active metabolites: o,p'-DDE (dichlorodiphenylethene) and o,p'-DDA (dichlorodiphenylacetate)."3.85Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. ( Allegra, S; Berruti, A; Carrella, S; Cusato, J; D'Avolio, A; Daffara, FC; De Francia, S; De Martino, F; Di Carlo, F; Ferrero, A; Piccione, FM; Pirro, E; Tampellini, M; Terzolo, M, 2017)
"Oral mitotane (o,p'-DDD) is a cornerstone of medical treatment for adrenocortical carcinoma (ACC)."3.83Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. ( Fassnacht, M; Heinz, W; Kendl, S; Klinker, H; Kroiss, M; Lapa, C; Plonné, D; Ronchi, CL; Sbiera, S; Schirbel, A; Schirmer, D; Zink, M, 2016)
"Current treatment guidelines recommend adjuvant mitotane after resection of adrenocortical carcinoma with high-risk features (eg, tumor rupture, positive margins, positive lymph nodes, high grade, elevated mitotic index, and advanced stage)."3.83Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. ( Duh, QY; Ethun, CG; Fields, RC; Gad, S; Glenn, J; Hatzaras, I; Jin, LX; Keplinger, K; Kiernan, CM; Levine, EA; Maithel, SK; Mansour, JC; Pawlik, TM; Phay, JE; Postlewait, LM; Poultsides, GA; Prescott, JD; Salem, A; Seiser, N; Shenoy, R; Sicklick, JK; Solorzano, CC; Staley, CA; Tran, TB; Votanopoulos, KI; Wang, TS; Weber, SM; Yopp, AC, 2016)
"Mitotane has been used for more than 5 decades as therapy for adrenocortical carcinoma (ACC)."3.83Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature. ( Bourdeau, I; Cohade, C; El Ghorayeb, N; Lacroix, A; Latour, M; Mazzuco, TL; Olney, H; Perrotte, P; Rondeau, G; Sabourin, A, 2016)
"Evaluation of patient characteristics and mitotane use in the treatment of adrenocortical carcinoma (ACC) over a 4-year period in Belgium."3.83Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients. ( Banh, C; Bex, M; Chadarevian, R; Gil, T; Maiter, D; T'Sjoen, G; Vroonen, L, 2016)
"Treatment of patients with adrenocortical carcinomas (ACC) with mitotane and/or chemotherapy is often associated with toxicity and poor tumor response."3.83Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene. ( Creemers, SG; de Herder, WW; Feelders, RA; Franssen, GJ; Hofland, LJ; Korpershoek, E; van den Dungen, ES; van Kemenade, FJ; van Koetsveld, PM, 2016)
"Mitotane is the only drug approved for treatment of the orphan disease adrenocortical carcinoma (ACC) and was recently shown to be the first clinically used drug acting through endoplasmic reticulum (ER)-stress induced by toxic lipids."3.83Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells. ( Fassnacht, M; Kendl, S; Kroiss, M; Kurlbaum, M; Sbiera, S, 2016)
"Mitotane is the drug of choice in medical treatment of adrenocortical carcinoma."3.81Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma. ( den Hartigh, J; Derijks, LJ; Ettaieb, H; Gelderblom, H; Guchelaar, HJ; Haak, HR; Kerkhofs, TM; Neef, K, 2015)
"Mitotane is an adrenolytic and anticortisolic drug used in adrenocortical carcinoma (ACC), Cushing's disease (CD), and ectopic ACTH syndrome."3.81Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease. ( Bachelot, A; Baudin, E; Bernard, V; Bry-Gauillard, H; Chanson, P; Crinière, L; Do Cao, C; Droumaguet, C; Guignat, L; Leboulleux, S; Maiter, D; Pierre, P; Salenave, S; Santulli, P; Schlumberger, M; Touraine, P; Young, J, 2015)
"Mitotane (o,p'-DDD), the only approved drug for advanced adrenocortical carcinoma (ACC), is a lipophilic agent that accumulates into circulating lipoprotein fractions and high-lipid-containing tissues."3.81Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma. ( Baudin, E; Broutin, S; Cockenpot, F; Guerin, M; Hescot, S; Huby, T; Lombès, M; Paci, A; Seck, A; Young, J, 2015)
"Mitotane (o,p'DDD) is the most effective treatment of advanced adrenocortical carcinoma (ACC) but its mechanism of action remains unknown."3.80The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment. ( Al Ghuzlan, A; Baudin, E; Brailly-Tabard, S; Hescot, S; Lombès, M; Paci, A; Seck, A; Slama, A; Trabado, S; Viengchareun, S; Young, J, 2014)
"Mitotane is currently employed as adjuvant therapy as well as in the medical treatment of adrenocortical carcinoma (ACC), alone or in combination with chemotherapeutic agents."3.80Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells. ( Benfini, K; Di Pasquale, C; Falletta, S; Feo, C; Gagliano, T; Gentilin, E; Tagliati, F; Tassinari, M; Uberti, ED; Zatelli, MC, 2014)
"We herein report a case of marked transient hypercholesterolemia in a man receiving low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma."3.80Marked transient hypercholesterolemia caused by low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma. ( Inazu, A; Kawashiri, MA; Mabuchi, H; Nohara, A; Tada, H; Yamagishi, M, 2014)
"Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC)."3.79Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. ( Al Ghuzlan, A; Allolio, B; Ardito, A; Baudin, AE; Berruti, A; Daffara, F; De Francia, S; deVries, JH; Fassnacht, M; Feelders, RA; Haak, HR; Kroiss, M; Leboulleux, S; Perotti, P; Terzolo, M; Volante, M; Zaggia, B, 2013)
"Mitotane is a widely used drug in the therapy of adrenocortical carcinoma (ACC)."3.79Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma. ( Doghman, M; Lalli, E, 2013)
"In patients with adrenocortical carcinoma (ACC) mitotane activity has been suggested to depend on plasma levels 14 mg/liter or greater and metabolite formation."3.77Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study. ( Allolio, B; Baudin, E; Berruti, A; Chadarevian, R; Daffara, F; den Hartigh, J; Fassnacht, M; Haak, HR; Hermsen, IG; Houterman, S; Leboulleux, S; Schlumberger, M; Terzolo, M, 2011)
"We present the case of a female patient with virilising adrenocortical carcinoma treated surgically who conceived during adjuvant treatment with mitotane."3.77Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report. ( Baszko-Błaszyk, D; Ochmańska, K; Sowiński, J; Waśko, R, 2011)
"Mitotane treatment in adrenocortical carcinoma (ACC) results in unreliable measurement of serum total cortisol (TC) levels because of an elevation in corticosteroid-binding globulin (CBG)."3.76Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. ( Ajodha, S; Akker, SA; Alexandraki, KI; Allolio, B; Christ-Crain, M; Drake, WM; Edwards, R; Fassnacht, M; Grossman, AB; Kaltsas, GA; le Roux, CW, 2010)
"Mitotane (o,p'-DDD) is considered to be the drug of choice in the treatment of nonresectable and metastasized adrenocortical carcinoma."3.76Development of microemulsion of mitotane for improvement of oral bioavailability. ( Ajana, I; Astier, A; Attivi, D; Demoré, B; Gibaud, S, 2010)
"To progress in the stratification of the first-line therapeutic management of metastatic adrenocortical carcinoma (ACC), we searched for prognostic parameters of survival in patients treated with combined mitotane- and cisplatinum-based chemotherapy as first-line."3.76Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. ( Al Ghuzlan, A; Baudin, E; Caillou, B; Castaing, M; Chanson, P; de Baere, T; Dromain, C; Elias, D; Leboulleux, S; Malandrino, P; Paci, A; Schlumberger, M; Travagli, JP; Young, J, 2010)
"Adjuvant mitotane may prolong recurrence-free survival in patients with radically resected adrenocortical carcinoma."3.74Adjuvant mitotane treatment for adrenocortical carcinoma. ( Allolio, B; Ambrosi, B; Angeli, A; Arvat, E; Berruti, A; Bollito, E; Bruzzi, P; Buci, L; Conton, PA; Daffara, F; Dogliotti, L; Fassnacht, M; Grossrubatscher, E; Hahner, S; Koschker, AC; Loli, P; Lombardi, G; Mannelli, M; Mantero, F; Papotti, M; Reimondo, G; Rossetto, R; Saeger, W; Sperone, P; Tauchmanova, L; Terzolo, M, 2007)
"Mitotane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chloro-phenyl) ethane (o,p'-DDD), is a compound that represents the effective agent in the treatment of the adrenocortical carcinoma (ACC), able to block cortisol synthesis."3.74Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. ( Borro, M; Brunetti, E; Bucci, B; Cerquetti, L; Gentile, G; Misiti, S; Piergrossi, P; Simmaco, M; Stigliano, A; Toscano, V, 2008)
"Surgery with immediate adjuvant long term mitotane administration was the most effective form of therapy for patients with adrenocortical carcinoma."3.69Adrenocortical carcinoma. A clinical study and treatment results of 52 patients. ( Kasperlik-Załuska, AA; Makowska, AM; Migdalska, BM; Zgliczyński, S, 1995)
"Mitotane is considered to be the drug of choice for patients with inoperable, recurrent and metastatic adrenocortical carcinoma, although a favourable effect of this drug on survival has never been documented."3.69Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. ( Fleuren, GJ; Goslings, BM; Haak, HR; Hermans, J; Krans, HM; Lentjes, EG; van de Velde, CJ, 1994)
"Cabazitaxel has a manageable toxicity profile but is poorly active as second/third-line treatment in advanced ACC patients."3.11Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma. ( Abate, A; Ambrosini, R; Berruti, A; Canu, L; Cosentini, D; Ferrari, VD; Gianoncelli, A; Grisanti, S; Laganà, M; Sigala, S; Terzolo, M; Tiberio, GAM; Turla, A; Zamparini, M, 2022)
"Although adrenocortical carcinoma (ACC) during pregnancy is rare, a retrospective review of a case series at our hospital revealed that almost one third of our patients were women in childbearing age."3.01Pregnancy in patients with adrenocortical carcinoma: a case-based discussion. ( Basile, V; Puglisi, S; Sperone, P; Terzolo, M, 2023)
" IMC-A12 was dosed at 10 mg/kg intravenously every 2 weeks."2.79The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial. ( Agamah, E; Else, T; Hammer, GD; Hasseltine, EA; Hesseltine, EA; Lerario, AM; Ramm, CA; Rao, K; Shah, MH; Stadler, WM; Worden, FP, 2014)
"Treatment of refractory adrenocortical carcinoma (ACC) is not established."2.77Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. ( Allolio, B; Fassnacht, M; Hahner, S; Johanssen, S; Kroiss, M; Lankheet, N; Laubner, K; Müller, HH; Pöllinger, A; Quinkler, M; Strasburger, CJ; van Erp, NP, 2012)
"Mitotane plasma levels were determined using high-performance liquid chromatography."2.72Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression. ( Callefe, LG; Ferman, S; Figueiredo, BC; Lichtvan, LL; Oliveira, BH; Parise, GA; Pianovski, MA; Piovezan, GC; Santana, MH; Stinghen, ST; Voss, SZ; Zancanella, P, 2006)
" The therapeutic range is close and therefore dosage is difficult, mainly based on clinical signs."2.70[Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels]. ( Heilmann, P; Nawroth, PP; Wagner, P; Ziegler, R, 2001)
"Adrenocortical carcinoma is a rare malignancy, often with poor outcomes."2.66American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach. ( Bancos, I; Else, T; Habra, M; Hamrahian, A; Kiseljak-Vassiliades, K; Levine, AC; Vaidya, A, 2020)
"Pheochromocytomas are present in approximately 4-7% of patients with adrenal incidentalomas."2.58Primary malignant tumors of the adrenal glands. ( Almeida, MQ; Bezerra-Neto, JE; Fragoso, MCBV; Latronico, AC; Mendonça, BB, 2018)
"Adrenocortical carcinoma is a rare disease with poor prognosis."2.55Understanding mitotane mode of action. ( Dworakowska, D; Szyszka, P; Waszut, U, 2017)
"Recent developments in the treatment of adrenocortical carcinoma (ACC) include diagnostic and prognostic risk stratification algorithms, increasing evidence of the impact of historical therapies on overall survival, and emerging targets from integrated epigenomic and genomic analyses."2.52Adrenocortical carcinoma. ( Baudin, E, 2015)
"Pheochromocytomas are derived from the adrenal medulla and present with symptoms caused by high secretion of catecholamines."2.50Rare adrenal tumors in children. ( Mihai, R, 2014)
"Adrenocortical carcinoma is a rare malignancy."2.50Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma. ( Nakamura, Y; Sasano, H; Satoh, F, 2014)
"Even after complete surgery, recurrence is frequent and adjuvant mitotane treatment improves outcome, but uncertainty exists as to whether all patients benefit from this therapy."2.49Update in adrenocortical carcinoma. ( Allolio, B; Fassnacht, M; Kroiss, M, 2013)
"Mitotane was stopped at gestation week 6."2.49Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature. ( Blumenfeld, Z; Bronshtein, M; Jaffe, A; Salmon, A; Tripto-Shkolnik, L, 2013)
"Adrenocortical carcinomas are rare in children and sometimes occur in patients with predisposing syndrome like Li-Fraumeni or Beckwith-Wiedemann syndromes."2.47[Management of adrenocortical carcinomas in children]. ( Aubert, S; Delebarre, M; Leblond, P, 2011)
"Adrenocortical carcinoma with tumor thrombus and concomitant testosterone production is a rare entity."2.47Surgical resection of a virilizing adrenal mass with extensive tumor thrombus. ( Ciancio, G; Gahan, J; Gorin, MA; Salerno, TA; Shirodkar, SP, 2011)
" Several important questions remain to be addressed such as the optimal dose and most effective dosing interval, when to use the metronomic approach in the natural history of the disease, the choice of cytotoxic drugs, and the most efficacious way to integrate metronomic chemotherapy with standard therapy protocols."2.47Metronomic therapy concepts in the management of adrenocortical carcinoma. ( Ardito, A; Bellini, E; Berruti, A; Daffara, F; Perotti, P; Saini, A; Sperone, P; Terzolo, M, 2011)
"Androgen-secreting adrenal cancers are extremely rare malignancies, accounting for only a tiny proportion of the total number of women presenting with signs of androgen excess."2.46Androgen- and estrogen-secreting adrenal cancers. ( Bharwani, N; Cavlan, D; Grossman, A, 2010)
"Sometimes the adrenocortical carcinoma is associated with tumour syndromes such as the Beckwith-Wiedemann and Li-Fraumeni syndrome; however, most tumours are sporadic."2.44Adrenocortical carcinoma. ( Haak, HR; van de Weijer, R; van Ditzhuijsen, CI, 2007)
"Mitotane has remained the preferred adjuvant treatment agent, showing modest effect in patients with unresectable, residual or metastatic disease."2.43Adrenocortical carcinoma. ( Roman, S, 2006)
"Therapy in patients with adrenocortical carcinoma is less satisfactory."2.42[Diagnosis and treatment for adrenocortical carcinoma]. ( Iihara, M; Obara, T, 2004)
"Adrenocortical carcinoma is a rare tumor with an annual incidence of 1 to 2 cases per million people."2.42[Adrenocortical carcinoma and its treatment]. ( Bednarek-Tupikowska, G; Florczak, A; Tupikowski, W, 2004)
"Adrenocortical cancers are relatively rare endocrine tumors that usually present when hormonally active or after they have become large and metastasis has occurred."2.40Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies. ( Demeure, MJ; Somberg, LB, 1998)
"To report a rare case of a metastatic adrenocortical carcinoma (ACC) that achieve a complete and a long-term remission."1.91Long-term complete remission of metastatic adrenocortical carcinoma. ( Álvarez-Escolá, C; Cárdenas-Salas, J; Castelo, B; González-Sanchez, JA; Regojo, RM, 2023)
"The management of adrenocortical carcinoma (ACC) recurrences remains controversial, and we present herein our experience with postoperative ACC recurrences."1.91The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients. ( Basile, V; Berchialla, P; Borin, C; Calabrese, A; Fiori, C; Perotti, P; Pia, A; Porpiglia, F; Puglisi, S; Reimondo, G; Terzolo, M; Veltri, A; Volante, M, 2023)
"Mitotane therapy was initiated in 29 patients in the postoperative period, 33 patients were under dynamic observation without concomitant drug treatment."1.91[Morphological predictors of the efficacy of mitotane therapy in adrenocortical cancer]. ( Beltsevich, DG; Porubayeva, EE; Tkachuk, AV; Urusova, LS, 2023)
"The prognosis of adrenocortical carcinoma (ACC) is poor but highly variable."1.91Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience. ( Huang, CJ; Lin, LY; Ng, XN; Pan, LH; Yen, CC, 2023)
"Because of the rarity of adrenocortical cancer (ACC), only a few population-based studies are available, and they reported limited details in the characterization of patients and their treatment."1.91New Findings on Presentation and Outcome of Patients With Adrenocortical Cancer: Results From a National Cohort Study. ( Altieri, B; Arvat, E; Basile, V; Berchialla, P; Berruti, A; Calabrese, A; Cannavò, S; Canu, L; Ceccato, F; Di Dalmazi, G; Ferraù, F; Fiori, C; Grisanti, S; Laganà, M; Loli, P; Morelli, V; Perotti, P; Pia, A; Pivonello, R; Porpiglia, F; Puglisi, S; Reimondo, G; Scaroni, C; Stigliano, A; Terzolo, M; Urru, S; Violi, MA, 2023)
"Adrenocortical carcinomas are rare tumors, usually hyperfunctioning, with poor overall survival."1.91[Adrenocortical carcinoma in women of reproductive age]. ( Bergoglio, MT; Damilano, RA, 2023)
"His aldosterone/renin ratio was high and plasma renin activity was low."1.91[A Case of Aldosterone-Producing Adrenocortical Carcinoma]. ( Asai, S; Hashimoto, K; Ishihara, M; Kanamaru, S; Katsushima, H; Nakayasu, R; Oshiro, H; Shimizu, Y; Son, C; Tsuji, K; Utsunomiya, N, 2023)
"Mitotane TR was significantly reduced in the SPL group, as was time-in-range to progression."1.72Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients. ( Haberbosch, L; Jumpertz von Schwartzenberg, R; Mai, K; Maurer, L; Sandforth, A; Spranger, J; Wernicke, C, 2022)
"Reporting temporal trends in adrenocortical carcinoma (ACC) helps guide management strategies."1.72Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience. ( Altameemi, L; Bazerbashi, H; Bedrose, S; Campbell, MT; Daher, M; Graham, PH; Gruschkus, SK; Habra, MA; Jimenez, C; Karam, JA; Lee, JE; Naing, A; Perrier, ND; Shah, AY; Sheth, RA; Subaiah, V; Varghese, J; Waguespack, SG; Wood, CG; Zhang, M, 2022)
"Mitotane (o, p'-DDD) is a molecule that was developed many years ago for adrenal cortical carcinoma, but no suitable pediatric dosage form is available for administration to young children."1.72Successful administration of mitotane (O, p'-DDD) in pediatric oncology. ( Defachelles, AS; Feutry, F; Fraipont, F; Marliot, G; Mercier, S; Naveau, M; Raimbault, S; Sakji, I; Stala, T; Strobbe, G; Villain, A, 2022)
"Mitotane chemotherapy is a standard but unproven adjuvant treatment that is associated with many complications, and its induction of hepatic CYP 3A4 enzymes necessitates adjustment of other medications."1.72Massive adrenocortical carcinoma presenting as peripheral edema: a case report. ( Goodkin, DA, 2022)
"The pathological diagnosis was adrenocortical carcinoma with negative surgical margin."1.72[A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission]. ( Iinuma, K; Kato, D; Kawase, K; Kawase, M; Koie, T; Miyazaki, T; Nakai, C; Nakane, K; Namiki, S; Takai, M; Takeuchi, S; Takeuchi, Y; Tsuchiya, T; Ueda, S, 2022)
"Pediatric and adult adrenocortical carcinomas differ in many respects but treatment is often similar in both age groups."1.62Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines? ( Berruti, A; Cosentini, D; Grisanti, S; Laganà, M; Turla, A, 2021)
"Widespread metastatic adrenocortical carcinoma was confirmed on biopsy."1.62A rare case of right shoulder pain. ( Bansari, A; Kattan, JN; Radhakrishnan, NS, 2021)
"Mitotane was administered to 2 patients as an adjuvant therapy and to 8 patients for systemic control."1.62Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma. ( Fukuda, N; Hayashi, N; Inamura, K; Komai, Y; Nakano, K; Numao, N; Ohmoto, A; Ono, M; Sato, Y; Shigematsu, Y; Takahashi, S; Tomomatsu, J; Urasaki, T; Wang, X; Yonese, J; Yuasa, T; Yunokawa, M, 2021)
"Mitotane (MT) has been used for treatment of ACC for decades, either alone or in combination with cytotoxic chemotherapy."1.56A Micellar Mitotane Formulation with High Drug-Loading and Solubility: Physico-Chemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models. ( Haider, MS; Kendl, S; Kroiss, M; Luxenhofer, R; Schreiner, J, 2020)
"Adjuvant therapy in adrenocortical carcinoma was initiated less frequently than suggested by current guidelines."1.56Clinical presentation, treatment modalities and outcome in patients with adrenocortical carcinoma: A single center experience. ( Bechter, OE; Bronswijk, MJH; Laenen, A, 2020)
"Mitotane is a key drug for the treatment of adrenal cortical carcinoma."1.56A simplified method for therapeutic drug monitoring of mitotane by gas chromatography-electron ionization-mass spectrometry. ( Ando, M; Fukushima, S; Hashida, T; Hirabatake, M; Sugioka, N; Yasui, H, 2020)
"Mitotane, the standard treatment for ACC, impairs adrenocortical steroid biosynthesis and cholesterol metabolism."1.56Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma. ( Basile, V; Biasi, F; Caccia, C; Germano, A; Iaia, N; Leoni, V; Poli, G; Puglisi, S; Rossin, D; Saba, L; Terzolo, M, 2020)
"Despite the rarity of extra-adrenal adrenocortical carcinoma, presentation with an acute abdomen may occur, and the tumor may be found anywhere in the adrenal embryonic pathway."1.56Extra-adrenal, non-functional adrenocortical carcinoma presenting with acute abdomen: a case report. ( Ghorbani-Abdehgah, A; Mirsharifi, A; Naybandi Atashi, S; Sadeghian, E; Vasei, M, 2020)
"Under the diagnosis of stage IV adrenocortical carcinoma, mitotane therapy was started in May 2013."1.51[A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP]. ( Hanai, T; Nakayama, T; Onuki, T; Suzuki, K; Yamashita, D, 2019)
"The management of patients with adrenocortical carcinoma (ACC) is challenging."1.51In vitro antitumor activity of progesterone in human adrenocortical carcinoma. ( Berruti, A; Bonini, SA; Bosisio, D; Claps, M; Cosentini, D; Dalmiglio, C; Facchetti, F; Fiorentini, C; Fisogni, S; Fragni, M; Grisanti, S; Memo, M; Missale, C; Rossini, E; Salvi, V; Sigala, S; Terzolo, M; Tiberio, GAM; Vezzoli, S, 2019)
"Mitotane 6 g/day was started as standard therapy but it was responsible for severe central nervous system (CNS) and gastrointestinal toxicities associated with a 10 kg body weight loss."1.51A case report of a TDM-guided optimization of mitotane for a safe and effective long-term treatment. ( Bacca, A; Bernini, G; Ciofi, L; Di Paolo, A, 2019)
"Mitotane effect was explored stratifying patients by staging (stage I-II vs stage III), hormone secretion (yes vs no) and Ki67 index."1.51Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence. ( Basile, V; Berchialla, P; Berruti, A; Calabrese, A; Perotti, P; Pia, A; Porpiglia, F; Puglisi, S; Reimondo, G; Saba, L; Terzolo, M; Veltri, A; Volante, M, 2019)
"Adrenocortical carcinoma is a rare and aggressive malignancy with an incidence of 0."1.51A clinical study and treatment results of adrenocortical carcinoma patients presented in Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore. ( Ali, A; Anwar, AW; Bakar, MA; Khan, MA; Khan, MS; Tariq, I, 2019)
"Mitotane treatment may be independently associated with better outcomes regardless of the tumor stage."1.48Prognostic factors in adrenocortical carcinoma: data from a large Polish series. ( Ambroziak, U; Cichocki, A; Koperski, Ł; Nowak, KM; Otto, M; Papierska, L; Roszkowska-Purska, K; Samsel, R; Zgliczyński, W; Łebek-Szatańska, A, 2018)
"Adrenal insufficiency is common with mitotane use and aggressive treatment with steroid supplementation should be considered when appropriate to avoid excess toxicities."1.46Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug. ( Chou, J; Gerst, S; Gopalan, A; Hrabovsky, A; Kampel, L; Katz, S; Kelly, C; Lung, B; Raj, N; Reidy-Lagunes, DL; Saltz, LB; Untch, BR, 2017)
"Adrenocortical carcinoma is a rare tumour with high malignancy and poor prognosis."1.46Use of a levonorgestrel-releasing intrauterine device for menorrhagia treatment during adjuvant therapy of adrenocortical carcinoma with mitotane. ( Czuczwar, P; Paszkowski, T; Szkodziak, F; Szkodziak, PR; Woźniak, S, 2017)
"Systemic therapy of adrenocortical carcinoma (ACC) is limited by heterogeneous tumor response and adverse effects."1.43Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma. ( Beuschlein, F; Fassnacht, M; Hantel, C; Igaz, P; Jung, S; Nagy, Z; Reincke, M; Weiss, M; Zambetti, G, 2016)
"Molecular characterization of adrenocortical cancer has deepened our understanding of this genetically complex disease while identifying subgroups whose importance remains to be determined."1.43Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters. ( Balasubramaniam, S; Bates, SE; Edgerly, M; Fojo, T; Leuva, H; Litman, T; Merino, MJ; Payabyab, EC; Velarde, M; Venkatesan, AM, 2016)
"Mitotane was administered in 12 (71 %) patients with stage III-IV ACCs with a 5-year survival rate 25 % compared to 20 % in patients who did not receive Mitotane."1.42Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm. ( Abdel-Aziz, TE; Mihai, R; Rajeev, P; Sadler, G; Weaver, A, 2015)
"We aimed at investigating in vitro the cytotoxic activity (determined using WST-1, apoptosis and cell cycle assays) of gemcitabine, alone or in combination with mitotane, in mitotane-sensitive H295R and mitotane-insensitive SW-13 cells."1.40Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. ( Berruti, A; Carturan, S; Germano, A; Lo Buono, N; Papotti, M; Rapa, I; Terzolo, M; Volante, M, 2014)
"Overt hypercortisolism was observed in 197 patients (37."1.40Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. ( Allolio, B; Ardito, A; Baudin, E; Berruti, A; Deutschbein, T; Else, T; Fassnacht, M; Feelders, R; Gelderblom, H; Grisanti, S; Haak, H; Hammer, GD; Kerkhofs, T; Kroiss, M; Leboulleux, S; Papotti, M; Porpiglia, F; Ronchi, C; Sperone, P; Terzolo, M; Volante, M; Williams, AR, 2014)
"Adrenocortical carcinoma is a rare malignant endocrine neoplasia."1.40Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. ( Else, T; Hammer, GD; Jolly, S; Miller, BS; Sabolch, A; Williams, AR, 2014)
"Mitotane treatment also led to decreased cortisol and DHEAS concentration in the culture media."1.39The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells. ( Jagodziński, PP; Lehmann, TP; Wrzesiński, T, 2013)
"The pregnancy was complicated by fetal exposure to mitotane and dexamethasone."1.37Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure. ( Burym, C; Cronin, CM; Kojori, F; Salamon, E; Sellers, EA, 2011)
"We report the first case of adrenocortical carcinoma secreting cortisol (Cushing's syndrome) and aldosterone (Conn's syndrome) with extensive distant metastasis at the time of diagnosis."1.37Metastatic adrenocortical carcinoma presenting simultaneously with Cushing's and Conn's syndromes: a case report. ( Bang, SM; Beom, SH; Choi, Y; Chung, JH; Kim, JH; Kim, YJ; Lee, JS; Lee, KW; Song, KH; Yang, Y, 2011)
"Median survival in stage II adrenocortical carcinoma (ACC) differs widely in published series ranging between 23 and more than 60 months."1.36Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. ( Agha, A; Allolio, B; Beuschlein, F; Fassnacht, M; Fenske, W; Führer, D; Hahner, S; Johanssen, S; Jurowich, C; Petersenn, S; Quinkler, M; Spahn, M; Weismann, D, 2010)
"In suspected nonmetastatic adrenocortical carcinoma (ACC) a careful preoperative diagnostic work up is needed including comprehensive endocrine analysis as recommended by the European Network for the Study of Adrenal Tumors (http://www."1.36What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? ( Allolio, B; Fassnacht, M, 2010)
"Drug therapy for adrenocortical carcinoma (ACC), a rare and lethal malignancy, is largely empirical and ineffective."1.35Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. ( Barlaskar, FM; Ben-Josef, E; Giordano, TJ; Hammer, GD; Heaton, JH; Kim, AC; Kuick, R; Spalding, AC; Thomas, DG, 2009)
"Cushing syndrome was diagnosed on the basis of a markedly elevated 24-hour urine free cortisol level and classic cushingoid features."1.35A patient with ectopic cortisol production derived from malignant testicular masses. ( Dluhy, RG; Jain, SH; Nosé, V; Sadow, PM, 2008)
"Establishing a database for adrenocortical carcinomas in the UK would contribute to our understanding of the management of this disease."1.35How is adrenocortical cancer being managed in the UK? ( Aspinall, SR; Bliss, RD; Harrison, BJ; Imisairi, AH; Lennard, TW; Scott-Coombes, D, 2009)
" Treatment resulted in an improvement of performance status and a reduction of the daily dosage of mitotane in all patients."1.35Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma. ( Bizzarri, G; Graziano, FM; Guglielmi, R; Pacella, CM; Pacella, S; Papini, E; Stasi, R, 2008)
"Local tumor recurrence is common in adrenocortical carcinoma (ACC) and is the most frequent cause for reoperation."1.33Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. ( Allolio, B; Fassnacht, M; Flentje, M; Hahner, S; Kenn, W; Koschker, AC; Polat, B, 2006)
"Because of the rarity of adrenocortical carcinoma, survival rates and the prognosis for patients who have undergone operation are not well known."1.31Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. ( Andreassian, B; Carnaille, B; Chapuis, Y; Charpenay, C; Cougard, P; Goudet, P; Henry, JF; Icard, P; Proye, C, 2001)
"A 58-year-old man had adrenocortical carcinoma in the right adrenal gland."1.30Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma. ( Demura, H; Hirohara, D; Kanazawa, M; Nomura, K; Sawada, T; Seki, M; Takasaki, K, 1999)
"We report here a new case of feminizing adrenocortical carcinoma revealed by a bilateral gynecomastia in a 50 year old man."1.29[Bilateral gynecomastia revealing malignant feminizing adrenocortical carcinoma]. ( Chraibi, A; Kadiri, A, 1994)

Research

Studies (257)

TimeframeStudies, this research(%)All Research%
pre-19903 (1.17)18.7374
1990's9 (3.50)18.2507
2000's45 (17.51)29.6817
2010's128 (49.81)24.3611
2020's72 (28.02)2.80

Authors

AuthorsStudies
Lehmann, TP1
Wrzesiński, T1
Jagodziński, PP1
Uchihara, M1
Tanioka, M1
Kojima, Y1
Nishikawa, T1
Sudo, K1
Shimoi, T1
Noguchi, E1
Maeshima, AM1
Yonemori, K1
Grisanti, S14
Cosentini, D11
Laganà, M9
Turla, A5
Berruti, A32
Bry-Gauillard, H2
Belin, F1
Vinolas, C1
Renoult-Pierre, P1
Massin, N1
Young, J6
Sifer, C1
Grynberg, M1
Abate, A4
Rossini, E3
Tamburello, M2
Fiorentini, C2
Tiberio, GAM3
Scatolini, M1
Grosso, E1
Hantel, C7
Memo, M2
Sigala, S7
Altieri, B6
Lalli, E4
Faggiano, A1
Hadoux, J3
Libè, R6
Frigerio, M1
Deschamps, F2
Zamparini, M2
Lamartina, L2
Pedersini, R1
Valsecchi, C1
Maroldi, R1
Al Ghuzlan, A6
Terzolo, M36
Gasparotti, R1
Baudin, E20
Haberbosch, L1
Maurer, L1
Sandforth, A1
Wernicke, C1
Spranger, J1
Mai, K1
Jumpertz von Schwartzenberg, R1
Daher, M1
Varghese, J2
Gruschkus, SK1
Jimenez, C1
Waguespack, SG1
Bedrose, S1
Altameemi, L1
Bazerbashi, H1
Naing, A1
Subaiah, V1
Campbell, MT1
Shah, AY1
Zhang, M1
Sheth, RA1
Karam, JA1
Wood, CG1
Perrier, ND2
Graham, PH1
Lee, JE3
Habra, MA3
Strobbe, G1
Fraipont, F1
Raimbault, S1
Mercier, S1
Stala, T1
Naveau, M1
Villain, A1
Sakji, I1
Defachelles, AS1
Feutry, F1
Marliot, G1
Ambrosini, R1
Ferrari, VD3
Gianoncelli, A1
Canu, L6
Lerario, AM3
Mohan, DR1
Hammer, GD8
Cremaschi, V3
Consoli, F1
Fassnacht, M38
Goodkin, DA1
Ueda, S1
Nakane, K1
Namiki, S1
Takeuchi, Y1
Kawase, M1
Takeuchi, S1
Kawase, K1
Nakai, C1
Kato, D1
Takai, M1
Iinuma, K1
Tsuchiya, T1
Miyazaki, T1
Koie, T1
Warde, KM2
Lim, YJ2
Ribes Martinez, E2
Beuschlein, F10
O'Shea, P2
Dennedy, MC2
Kuhlen, M1
Mier, P1
Kunstreich, M1
Lessel, L1
Schneider, D1
Brecht, I1
Schewe, DM1
Frühwald, MC1
Vorwerk, P1
Redlich, A1
Cárdenas-Salas, J1
Castelo, B1
Regojo, RM1
González-Sanchez, JA1
Álvarez-Escolá, C2
Ren, L1
Yang, Y2
Li, W1
Zheng, X1
Liu, J1
Li, S1
Yang, H1
Zhang, Y1
Ge, B1
Zhang, S1
Fu, W1
Dong, D1
Du, G1
Wang, J1
Tőke, J1
Uhlyarik, A1
Lohinszky, J1
Stark, J1
Huszty, G1
Micsik, T1
Borka, K1
Reismann, P1
Horányi, J1
Igaz, P2
Tóth, M1
Sarvestani, AL1
Gregory, SN1
Teke, ME1
Hernandez, JM1
Padua, TC1
Marandino, L1
Raggi, D1
Hallanger-Johnson, J1
Kutikov, A1
Spiess, PE1
Necchi, A1
Ilanchezhian, M3
Varghese, DG3
Glod, JW3
Reilly, KM3
Widemann, BC3
Pommier, Y3
Kaplan, RN3
Del Rivero, J3
Puglisi, S11
Basile, V11
Sperone, P8
Brönimann, S3
Garstka, N3
Remzi, M3
LaPensee, CR1
Calabrese, A4
Borin, C1
Perotti, P10
Pia, A5
Berchialla, P4
Volante, M9
Fiori, C2
Porpiglia, F7
Veltri, A2
Reimondo, G7
Hassan, I1
Sheikh, A1
Tkachuk, AV1
Beltsevich, DG1
Porubayeva, EE1
Urusova, LS1
Mangone, A1
Detomas, M1
Prete, A1
Abbas, H2
Asia, M1
Elhassan, YS1
Mantovani, G1
Ronchi, CL7
Poirier, J2
Godemel, S1
Mourot, A1
Grunenwald, S2
Olney, HJ1
Le, XK1
Lacroix, A4
Caron, P4
Bourdeau, I3
Kenney, L1
Hughes, M1
Pan, LH1
Yen, CC1
Huang, CJ1
Ng, XN1
Lin, LY1
Ferraù, F1
Violi, MA1
Ceccato, F1
Scaroni, C1
Di Dalmazi, G1
Stigliano, A5
Loli, P4
Pivonello, R2
Arvat, E3
Morelli, V1
Urru, S1
Cannavò, S1
Delbarba, A1
Facondo, P1
Pezzaioli, LC1
Alberti, A1
Cappelli, C1
Ferlin, A1
Damilano, RA1
Bergoglio, MT1
Hescot, S7
Debien, V1
Drui, D2
Haissaguerre, M3
de la Fouchardiere, C3
Vezzosi, D2
Do Cao, C3
Le Tourneau, C1
Massard, C1
du Rusquec, P1
Oshiro, H2
Shimizu, Y1
Nakayasu, R1
Utsunomiya, N1
Son, C1
Tsuji, K1
Asai, S1
Katsushima, H1
Ishihara, M1
Hashimoto, K1
Kanamaru, S1
Kastelan, D1
Arlt, W3
Haak, HR14
Decoudier, B1
Lasolle, H1
Quinkler, M8
Chabre, O1
Giordano, R1
Zatelli, MC2
Bancos, I2
Fragoso, MCBV3
Luconi, M4
Kroiss, M19
Megerle, F4
Hahner, S12
Kimpel, O1
Dusek, T1
Nölting, S1
Chortis, V2
Ettaieb, MH2
Bovis, F1
Sormani, MP1
Bruzzi, P2
Bertherat, J4
Cantini, G1
Niccolai, E1
Di Gloria, L1
Baldi, S1
Propato, AP1
Fei, L1
Nannini, G1
Nesi, G1
Ramazzotti, M1
Amedei, A1
Stadler, G1
de Almeida Veiga, A1
Rita Corso, C1
Bach de Assis, C1
de Toledo Nogueira, B1
Regina Rocha Martins, L1
Cruz Bonk, B1
Lada Degaut Pontes, F1
Cavalcante de Figueiredo, B1
Mera de Souza, L1
Weng, Y1
Wang, L1
Wang, XY1
Fan, XX1
Yan, L1
Li, ZH1
Zhang, SL1
Nowak, KM2
Łebek-Szatańska, A2
Samsel, R2
Roszkowska-Purska, K2
Ćwikła, JB1
Papierska, L2
van Koetsveld, PM4
Creemers, SG3
Dogan, F1
Franssen, GJH1
de Herder, WW6
Feelders, RA8
Hofland, LJ5
Haider, MS2
Schreiner, J2
Kendl, S5
Luxenhofer, R2
Belavgeni, A1
Bornstein, SR2
von Mässenhausen, A1
Tonnus, W1
Stumpf, J1
Meyer, C1
Othmar, E1
Latk, M1
Kanczkowski, W1
Hugo, C1
Ziegler, CG1
Schally, AV1
Krone, NP1
Linkermann, A1
Bronswijk, MJH1
Laenen, A1
Bechter, OE1
Ando, M1
Hirabatake, M1
Yasui, H1
Fukushima, S1
Sugioka, N1
Hashida, T1
Yamashita, D1
Hanai, T1
Onuki, T1
Suzuki, K1
Nakayama, T1
Germano, A3
Rossin, D1
Leoni, V1
Iaia, N1
Saba, L3
Caccia, C1
Poli, G2
Biasi, F1
Schoenmakers, E1
Leonard, M1
Lawless, SJ1
Chatterjee, KV1
Gurnell, M1
Abrahamsson, G1
Ekerhovd, E1
Janson, PO1
Jansson, S3
Ahlman, H3
Wängberg, B3
Norström, A1
Zancanella, P2
Oliveira, DML1
de Oliveira, BH1
Woiski, TD1
Pinto, CC1
Santana, MHA1
Souto, EB1
Severino, P1
Weigand, I3
Lacombe, AMF1
Kircher, S1
Landwehr, LS1
Zerbini, MCN1
Paiva, I2
Della Casa, S1
Sbiera, S7
Trotta, F1
Avena, P1
Chimento, A1
Rago, V1
De Luca, A1
Sculco, S1
Nocito, MC1
Malivindi, R1
Fallo, F1
Pezzani, R1
Pilon, C1
Lasorsa, FM1
Barile, SN1
Palmieri, L1
Pezzi, V1
Casaburi, I1
Sirianni, R1
Yin, A1
Ettaieb, MHT2
Swen, JJ1
van Deun, L1
Kerkhofs, TMA2
van der Straaten, RJHM1
Corssmit, EPM1
Gelderblom, H8
Kerstens, MN1
Eekhoff, M1
Timmers, HJLM1
D'Avolio, A2
Cusato, J2
Guchelaar, HJ4
Moes, DJAR1
Mirsharifi, A1
Vasei, M1
Sadeghian, E1
Ghorbani-Abdehgah, A1
Naybandi Atashi, S1
Salle, L1
Mas, R1
Teissier-Clément, MP1
Vikner, ME1
Krogh, J1
Daugaard, G1
Andreassen, M1
Liu, X1
Fu, Q1
Tang, Y2
Deng, JH1
Mei, D1
Zhang, B1
Loewe, R1
Rogowski-Lehmann, N1
Pfluger, T1
Reincke, M4
Bluemel, C2
De Filpo, G1
Mannelli, M5
Corso, CR1
Acco, A1
Bach, C1
Bonatto, SJR2
de Figueiredo, BC1
de Souza, LM1
Bansari, A1
Radhakrishnan, NS1
Kattan, JN1
Rodriguez-Galindo, C1
Krailo, MD1
Pinto, EM1
Pashankar, F1
Weldon, CB1
Huang, L1
Caran, EM1
Hicks, J1
McCarville, MB1
Malkin, D1
Wasserman, JD1
de Oliveira Filho, AG1
LaQuaglia, MP1
Ward, DA1
Zambetti, G2
Mastellaro, MJ1
Pappo, AS1
Ribeiro, RC1
Kiseljak-Vassiliades, K1
Hamrahian, A1
Habra, M1
Vaidya, A1
Levine, AC1
Else, T6
Steenaard, RV1
Goyzueta Mamani, LD1
de Carvalho, JC1
Tanobe, VAO1
Soccol, CR1
Carminati, O1
Rosti, G1
Boilève, A1
Mathy, E1
Roux, C1
Faron, M1
Tselikas, L1
Leboulleux, S12
de Baere, T2
Ohmoto, A1
Shigematsu, Y1
Fukuda, N1
Wang, X1
Urasaki, T1
Hayashi, N1
Sato, Y1
Nakano, K1
Yunokawa, M1
Ono, M1
Komai, Y1
Numao, N1
Yuasa, T1
Yonese, J1
Tomomatsu, J1
Inamura, K1
Takahashi, S1
Ahmad, T1
Groll, J1
Scherf-Clavel, O1
Pulzer, A3
Claps, M3
Daffara, F6
Boscaro, M1
Tiberio, G1
Zaggia, B3
Borges, KS1
Andrade, AF1
Silveira, VS1
Marco Antonio, DS1
Vasconcelos, EJR1
Antonini, SRR1
Tone, LG1
Scrideli, CA1
Waszut, U1
Szyszka, P1
Dworakowska, D1
Reidy-Lagunes, DL1
Lung, B1
Untch, BR1
Raj, N1
Hrabovsky, A1
Kelly, C1
Gerst, S1
Katz, S1
Kampel, L1
Chou, J1
Gopalan, A1
Saltz, LB1
Taza, F1
Chovanec, M1
Hahn, N1
Albany, C1
Cabezón-Gutiérrez, L1
Khosravi-Shahi, P1
Custodio-Cabello, S1
Lujan-Rodríguez, DR1
Garijo-Álvarez, JÁ1
Causso-Lariena, CM1
Franco-Moreno, AI1
De Francia, S4
Allegra, S1
Carrella, S1
Pirro, E1
Piccione, FM1
De Martino, F1
Ferrero, A2
Daffara, FC1
Di Carlo, F1
Tampellini, M1
Cerri, S1
Lazzari, B1
Ferrari, V1
Roca, E2
Bongard, V1
Illouz, F1
Borson-Chazot, F1
Djobo, B1
Berdelou, A2
Tabarin, A3
Schlumberger, M6
Briet, C1
Pape, E1
Feliu, C1
Yéléhé-Okouma, M1
Colling, N1
Djerada, Z1
Gambier, N1
Weryha, G1
Scala-Bertola, J1
Szkodziak, PR1
Czuczwar, P1
Woźniak, S1
Szkodziak, F1
Paszkowski, T1
Herrmann, W1
Schloetelburg, W1
Ruggiero, C1
Doghman-Bouguerra, M2
Ronco, C1
Benhida, R1
Rocchi, S1
Cichocki, A1
Ambroziak, U1
Koperski, Ł1
Otto, M1
Zgliczyński, W1
Rapa, I2
Shuayb, M1
Das, A1
Uddin, MN1
Liu, Z1
Zou, Z1
Liang, J1
Lu, Y1
Zhu, Y2
Arshad, U1
Taubert, M1
Kurlbaum, M2
Frechen, S1
Herterich, S1
Hamacher, S1
Fuhr, U1
Farooq, AU1
Amjad, W1
Kochar, T1
Adhikari, S1
Dickson, PV1
Kim, L1
Yen, TWF1
Yang, A1
Grubbs, EG2
Patel, D1
Solórzano, CC2
Dekkers, OM1
de Krijger, R1
Mihai, R4
Assie, G1
Sbiera, I3
Fragni, M1
Fisogni, S1
Vezzoli, S1
Bonini, SA1
Dalmiglio, C1
Salvi, V1
Bosisio, D1
Missale, C1
Facchetti, F1
Almeida, MQ1
Bezerra-Neto, JE1
Mendonça, BB1
Latronico, AC1
Di Paolo, A1
Ciofi, L1
Bacca, A1
Bernini, G1
Boulate, G1
Amazit, L1
Naman, A1
Seck, A3
Paci, A6
Lombes, A1
Pussard, E1
Lombes, M4
Khan, MS1
Ali, A1
Tariq, I1
Khan, MA1
Bakar, MA1
Anwar, AW1
Komarowska, H1
Ruciński, M1
Fichna, M1
Bromińska, B1
Iżycki, D1
Czarnywojtek, A1
Ruchała, M1
Tierney, JF1
Chivukula, SV1
Pappas, SG1
Schadde, E1
Hertl, M1
Kebebew, E1
Keutgen, X1
Freire, DS1
Siqueira, SA1
Zerbini, MC1
Wajchenberg, BL1
Corrêa-Giannella, ML1
Lucon, AM1
Pereira, MA1
Vitale, G1
Waaijers, M1
Sprij-Mooij, DM1
de Krijger, RR2
Speel, EJ1
Hofland, J1
Lamberts, SW2
Hermsen, IG3
Kerkhofs, TM4
Wilmink, H2
Smit, JW1
de Miranda, NF1
van Eijk, R1
van Wezel, T1
Morreau, H1
Baudin, AE1
Ardito, A3
deVries, JH1
Allolio, B18
Doghman, M1
Lo Buono, N1
Carturan, S1
Papotti, M5
Chadarevian, R3
Mueller, HH1
Skogseid, B3
Mantero, F5
Haak, H3
Kerkhofs, T1
Williams, AR3
Deutschbein, T3
Feelders, R1
Ronchi, C1
Sabolch, A1
Jolly, S1
Miller, BS1
Jung, S3
Mussack, T2
FISHER, DA1
PANOS, TC1
MELBY, JC1
Manenschijn, L1
van Rossum, EF1
Allasino, B1
Worden, FP1
Ramm, CA1
Hesseltine, EA1
Hasseltine, EA1
Stadler, WM1
Shah, MH1
Agamah, E1
Rao, K1
Derijks, LJ2
Ettaieb, H1
den Hartigh, J4
Neef, K1
Slama, A1
Viengchareun, S1
Trabado, S1
Brailly-Tabard, S1
Gagliano, T1
Gentilin, E1
Benfini, K1
Di Pasquale, C1
Tassinari, M1
Falletta, S1
Feo, C1
Tagliati, F1
Uberti, ED1
Pal, SK1
Gartrell, B1
Olsson, CA1
Stein, CA1
Steinhauer, S1
Scott-Wild, V1
Bala, M2
Eekhoff, EM1
Neef, C1
Sasano, H2
Satoh, F1
Nakamura, Y1
Tada, H1
Nohara, A1
Kawashiri, MA1
Inazu, A1
Mabuchi, H1
Yamagishi, M1
Salenave, S1
Bernard, V1
Guignat, L1
Bachelot, A1
Droumaguet, C1
Pierre, P1
Crinière, L1
Santulli, P1
Touraine, P1
Chanson, P3
Maiter, D2
Abdel-Aziz, TE1
Rajeev, P1
Sadler, G1
Weaver, A1
Ranvier, GG1
Inabnet, WB1
Guerin, M1
Cockenpot, F1
Huby, T1
Broutin, S1
Baur, J1
Schedelbeck, U1
Wild, V1
Steger, U1
Leich, E1
Liebisch, G1
Schirbel, A2
Wiemer, L1
Matysik, S1
Eckhardt, C1
Gardill, F1
Gehl, A1
Schmitz, G1
Rosenwald, A1
Zhuang, J1
Wang, D1
Wu, R1
Tu, X1
Chen, Y1
Qiu, S1
Mayor-Ibarguren, A1
Roldán-Puchalt, MC1
Gómez-Fernández, C1
Albízuri-Prado, F1
Korpershoek, E2
Franssen, GJ2
van Kemenade, FJ2
De Martino, MC1
Colao, A1
Plonné, D1
Schirmer, D1
Zink, M1
Lapa, C1
Klinker, H1
Heinz, W1
Xu, Y1
Dong, B1
Huang, J1
Kong, W1
Xue, W1
Zhang, J1
Huang, Y1
Postlewait, LM1
Ethun, CG1
Tran, TB1
Prescott, JD1
Pawlik, TM1
Wang, TS1
Glenn, J1
Hatzaras, I1
Shenoy, R1
Phay, JE1
Keplinger, K1
Fields, RC1
Jin, LX1
Weber, SM1
Salem, A1
Sicklick, JK1
Gad, S1
Yopp, AC1
Mansour, JC1
Duh, QY1
Seiser, N1
Kiernan, CM1
Votanopoulos, KI1
Levine, EA1
Staley, CA1
Poultsides, GA1
Maithel, SK1
Guelho, D1
Vieira, A1
Carrilho, F1
El Ghorayeb, N1
Rondeau, G1
Latour, M1
Cohade, C1
Olney, H1
Perrotte, P1
Sabourin, A1
Mazzuco, TL1
Bex, M1
Vroonen, L1
T'Sjoen, G1
Gil, T1
Banh, C1
Joppi, R1
Gerardi, C1
Bertele', V1
Garattini, S1
Granatiero, V1
Lacas-Gervais, S1
Brau, F1
Rizzuto, R1
Nagy, Z1
Weiss, M1
van den Dungen, ES1
Dralle, H3
Wahab, NA1
Zainudin, S1
AbAziz, A1
Mustafa, N1
Sukor, N1
Kamaruddin, NA1
Payabyab, EC1
Balasubramaniam, S2
Edgerly, M2
Velarde, M1
Merino, MJ1
Venkatesan, AM1
Leuva, H1
Litman, T1
Bates, SE1
Fojo, T5
Shapiro, I1
Chiapponi, C1
Bidlingmaier, M1
Caramella, C1
Cerquetti, L3
Bucci, B3
Marchese, R2
Misiti, S3
De Paula, U2
Miceli, R1
Muleti, A1
Amendola, D2
Piergrossi, P2
Brunetti, E3
Toscano, V3
Advani, A1
Vaikkakara, S1
Gill, MS1
Arun, CS1
Pearce, SH1
Ball, SG1
James, RA1
Lennard, TW2
Bliss, RD2
Quinton, R1
Johnson, SJ1
Fareau, GG1
Lopez, A1
Stava, C1
Vassilopoulou-Sellin, R2
Dogliotti, L3
Angeli, A3
Arai, H1
Rino, Y1
Yamanaka, S2
Yukawa, N1
Wada, N1
Kato, H1
Yanagimachi, M1
Goto, H1
Inayama, Y1
Lee, J1
Masuda, M1
Barlaskar, FM1
Spalding, AC1
Heaton, JH1
Kuick, R1
Kim, AC1
Thomas, DG1
Giordano, TJ1
Ben-Josef, E1
Jain, SH1
Sadow, PM1
Nosé, V1
Dluhy, RG1
Patalano, A1
Brancato, V1
Alexandraki, KI1
Kaltsas, GA1
le Roux, CW1
Ajodha, S1
Christ-Crain, M1
Akker, SA1
Drake, WM1
Edwards, R1
Grossman, AB1
Aspinall, SR1
Imisairi, AH1
Scott-Coombes, D1
Harrison, BJ1
Chalasani, S1
Vats, HS1
Banerjee, TK1
McKenzie, AK1
Strosberg, JR1
Doherty, GM1
Veytsman, I1
Nieman, L1
Attivi, D1
Ajana, I1
Astier, A1
Demoré, B1
Gibaud, S1
Callender, GG1
Xing, Y1
Evans, DB1
Phan, AT1
Khorram-Manesh, A2
Nilsson, B1
Nilsson, O2
Jakobsson, CE1
Lindstedt, S2
Odén, A1
Hammer, G1
Malandrino, P1
Castaing, M1
Caillou, B1
Travagli, JP1
Elias, D1
Dromain, C1
Sampaoli, C1
Raza, G1
Johanssen, S3
Fenske, W1
Weismann, D2
Agha, A1
Führer, D1
Jurowich, C1
Petersenn, S1
Spahn, M1
Sane, T1
Cavlan, D1
Bharwani, N1
Grossman, A1
van Erp, NP2
Ploeger, BA1
Romijn, JA1
Hartigh, Jd1
Houterman, S1
Baszko-Błaszyk, D1
Ochmańska, K1
Waśko, R1
Sowiński, J1
Leblond, P1
Delebarre, M1
Aubert, S1
Kojori, F1
Cronin, CM1
Salamon, E1
Burym, C1
Sellers, EA1
Gahan, J1
Shirodkar, SP1
Gorin, MA1
Salerno, TA1
Ciancio, G1
Zini, L1
Lutz, WK1
Costa, R1
Wesolowski, R1
Raghavan, D1
Bellini, E1
Saini, A1
Beom, SH1
Lee, KW1
Choi, Y1
Song, KH1
Kim, YJ1
Kim, JH1
Bang, SM1
Chung, JH1
Lee, JS1
Mauclère-Denost, S1
Borget, I1
Deandreis, D1
Drouard, L1
Demeure, MJ3
Bussey, KJ2
Kirschner, LS2
Mornar, A1
Sertić, M1
Turk, N1
Nigović, B1
Koršić, M1
Lin, CW1
Chang, YH1
Pu, HF1
Welin, S1
Schade-Brittinger, C1
Jarzab, B1
Sorbye, H1
Torpy, DJ1
Stepan, V1
Schteingart, DE2
Sundin, A1
Hermsen, I1
Willenberg, HS2
Sender, M1
Kenn, W2
Müller, HH2
Lankheet, N1
Pöllinger, A1
Laubner, K1
Strasburger, CJ1
Bapat, AA1
Menaa, F1
Menaa, B1
Pentheroudakis, G1
Ederhy, S1
Cohen, A1
Dufaitre, G1
Chaderevian, R1
Bertagna, X3
Taylor, AE1
Schneider, P1
Tomlinson, JW1
Hughes, BA1
O'Neil, DM1
Karavitaki, N1
Opocher, G1
Porfiri, E1
Sherlock, M1
Nightingale, P1
Shackleton, CH1
Stewart, PM1
Tripto-Shkolnik, L1
Blumenfeld, Z1
Bronshtein, M1
Salmon, A1
Jaffe, A1
MONTGOMERY, DA1
WELBOURN, RB1
MOLNAR, GD1
NUNN, SL1
TAUXE, WN1
Kvacheniuk, AM1
Iihara, M1
Obara, T1
Yoshimasu, T1
Oura, S1
Hirai, I1
Kokawa, Y1
Nishida, M1
Sasaki, R1
Tanino, H1
Sakurai, T1
Okamura, Y1
Inagaki, T1
Kodama, Y1
Shinke, T1
Tupikowski, W1
Bednarek-Tupikowska, G1
Florczak, A1
Brauckhoff, M1
Bacchetta, J1
Droz, JP1
Roman, S1
Suzuki, T1
Papewalis, C1
Domberg, J1
Fenk, R1
Rohr, UP1
Schinner, S1
Scherbaum, WA1
Schott, M1
Polat, B1
Koschker, AC3
Flentje, M1
Pianovski, MA1
Oliveira, BH1
Ferman, S1
Piovezan, GC1
Lichtvan, LL1
Voss, SZ1
Stinghen, ST1
Callefe, LG1
Parise, GA1
Santana, MH1
Figueiredo, BC1
Lecka, A1
Ginalska-Malinowska, M1
van Ditzhuijsen, CI1
van de Weijer, R1
Pacella, CM1
Stasi, R1
Bizzarri, G1
Pacella, S1
Graziano, FM1
Guglielmi, R1
Papini, E1
Tauchmanova, L1
Conton, PA1
Rossetto, R1
Buci, L1
Grossrubatscher, E1
Bollito, E1
Saeger, W1
Ambrosi, B1
Lombardi, G1
Carmona-Bayonas, A1
Soler, IO1
Gómez, FI1
Billalabeitia, EG1
Saura, HP1
Tafalla, MS1
Díaz, MP1
Coste, J1
Machens, A1
Dickstein, G1
Shechner, C1
Nativ, O1
Brix, D1
Riedmiller, H1
Borro, M1
Gentile, G1
Simmaco, M1
Ozimek, A1
Diebold, J1
Linke, R1
Heyn, J1
Hallfeldt, K1
Kasperlik-Załuska, AA2
Migdalska, BM2
Zgliczyński, S1
Makowska, AM2
Kadiri, A1
Chraibi, A1
Guinee, VF1
Hermans, J1
van de Velde, CJ1
Lentjes, EG1
Goslings, BM1
Fleuren, GJ1
Krans, HM1
Wooten, MD1
King, DK1
Somberg, LB1
Williamson, SK1
Lew, D1
Miller, GJ1
Balcerzak, SP1
Baker, LH1
Crawford, ED1
Seki, M1
Nomura, K1
Hirohara, D1
Kanazawa, M1
Sawada, T1
Takasaki, K1
Demura, H1
Heilmann, P1
Wagner, P1
Nawroth, PP1
Ziegler, R1
Icard, P1
Goudet, P1
Charpenay, C1
Andreassian, B1
Carnaille, B1
Chapuis, Y1
Cougard, P1
Henry, JF1
Proye, C1
Jacobsson, CE1
Syme, HM1
Scott-Moncrieff, JC1
Treadwell, NG1
Thompson, MF1
Snyder, PW1
White, MR1
Oliver, JW1
Ichikawa, T1
Ito, H1
Abraham, J1
Bakke, S1
Rutt, A1
Meadows, B1
Merino, M1
Alexander, R1
Schrump, D1
Bartlett, D1
Choyke, P1
Robey, R1
Hung, E1
Steinberg, SM1
Bates, S1

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Impact of Mitotane Therapy on Serum Free Proteins in Patients With Adrenocortical Carcinoma[NCT05344027]35 participants (Actual)Observational2022-04-11Completed
Multicenter, Prospective, Non-randomized, Phase II Trial Designed to Evaluate the Activity of Cabazitaxel in Patients With Advanced Adreno-Cortical- Carcinoma Progressing After Previous Chemotherapy Lines[NCT03257891]Phase 225 participants (Anticipated)Interventional2018-01-25Recruiting
Deutsches Nebennieren-Karzinom-Register - German Adrenocortical Carcinoma Registry[NCT00453674]1,000 participants (Anticipated)Observational2003-01-31Recruiting
Metabolic, Pressor and Neuropsychological Effects of Metyrapone Treatment in Patients With Hypercortisolism[NCT05255900]20 participants (Anticipated)Observational2022-04-28Recruiting
Prospective, Phase II Study to Evaluate the Efficacy of Addition of Progesterone to Standard Chemotherapy According to Etoposide-Doxorubicin-Cisplatin Scheme Plus Mitotane (EDP-M) in Patients With Advanced Adrenocortical Carcinoma (ACC)[NCT05913427]Phase 280 participants (Anticipated)Interventional2022-06-08Recruiting
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence[NCT03723941]Phase 3240 participants (Anticipated)Interventional2018-07-01Recruiting
Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma[NCT03145285]Phase 210 participants (Anticipated)Interventional2017-04-18Active, not recruiting
Natural History and Tissue Acquisition Study of Adrenocortical Carcinoma[NCT02015026]67 participants (Actual)Observational2013-12-13Completed
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)[NCT06141369]21 participants (Anticipated)Interventional2023-12-01Not yet recruiting
First International Randomized Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment[NCT00094497]Phase 3304 participants (Actual)Interventional2004-06-30Completed
Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy[NCT00453895]Phase 239 participants (Actual)Interventional2007-07-31Completed
Efficacy of Adjuvant Mitotane Treatment in Prolonging Recurrence-free Survival in Patients With Adrenocortical Carcinoma at Low-intermediate Risk of Recurrence[NCT00777244]Phase 3200 participants (Anticipated)Interventional2008-04-30Recruiting
Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy[NCT00786110]Phase 230 participants (Anticipated)Interventional2008-04-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Quality of Life as Measured by QLQ-C30

scale ranged from 0 to 100 with higher score meaning greater quality of life (NCT00094497)
Timeframe: baseline and 8 weeks

Interventionunits on a scale (Mean)
EDP-M-6.0
Sz-M-7.7

Number of Disease-free Patients

complete response or disease-free by time of surgery (NCT00094497)
Timeframe: every 8 weeks until progression (up to 5 years)

Interventionparticipants (Number)
EDP-M6
Sz-M3

Overall Survival

participants who died among those randomized to first-line therapy (NCT00094497)
Timeframe: every 8 weeks until death up to 5 years

Interventionparticipants (Number)
EDP-M108
Sz-M124

Progression-free Survival

(NCT00094497)
Timeframe: every 8 weeks until progression or death up to 5 years

Interventionmonths (Median)
EDP-M5.0
Sz-M2.1

Best Overall Response Rate

RECIST 1.0 was used to evaluate response (NCT00094497)
Timeframe: every 8 weeks up to 5 years

,
Interventionparticipants (Number)
complete responsedisease-free by time of surgerypartial responsestable diseaseprogressive diseasedid not receive treatmentcould not be evaluated
EDP-M24295343317
Sz-M12113488413

Assessment of Clinical Benefit Due to Treatment With Sunitinib

Clinical benefit was defined as stable disease or better for at least 12 weeks (NCT00453895)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Sunitinib5

Assessment of Objective Response Rates

Objective Response Rate defined by RECIST 1.0 (NCT00453895)
Timeframe: 12 weeks

InterventionParticipants (Count of Participants)
Sunitinib0

Assessment of Overall Survival

Overall Survival was defined as time from start of treatment until death or last follow-up. (NCT00453895)
Timeframe: up to 36 months

Interventionmonhts (Median)
Sunitinib5.4

Assessment of Progression-free Survival

Progression-free survival is defined as time of start of study until documentation of Progress. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions (NCT00453895)
Timeframe: up to 400 days

Interventiondays (Median)
Sunitinib83

Assessment of Toxicity

Adverse events were rated using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (see http://ctep.cancer.gov/reporting/ctc.html). (NCT00453895)
Timeframe: up to 400 days

Interventionnumber of adverse events/patient (Median)
Sunitinib4

Reviews

63 reviews available for mitotane and Adrenocortical Carcinoma

ArticleYear
Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen.
    Endocrine, 2022, Volume: 77, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols;

2022
ENDOCRINE TUMOURS: Our experience with the management of patients with non-metastatic adrenocortical carcinoma.
    European journal of endocrinology, 2022, Sep-01, Volume: 187, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Humans;

2022
Advances in adrenocortical carcinoma pharmacotherapy: what is the current state of the art?
    Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:12

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Antineoplastic Combined C

2022
A Systematic Review of Published Clinical Trials in the Systemic Treatment of Adrenocortical Carcinoma: An Initiative Led on Behalf of the Global Society of Rare Genitourinary Tumors.
    Clinical genitourinary cancer, 2023, Volume: 21, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols;

2023
Pediatric adrenocortical carcinoma.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito

2022
Pediatric adrenocortical carcinoma.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito

2022
Pediatric adrenocortical carcinoma.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito

2022
Pediatric adrenocortical carcinoma.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito

2022
Pediatric adrenocortical carcinoma.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito

2022
Pediatric adrenocortical carcinoma.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito

2022
Pediatric adrenocortical carcinoma.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito

2022
Pediatric adrenocortical carcinoma.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito

2022
Pediatric adrenocortical carcinoma.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Child; Humans; Li-Fraumeni Syndrome; Mito

2022
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
    Reviews in endocrine & metabolic disorders, 2023, Volume: 24, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro

2023
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
    Reviews in endocrine & metabolic disorders, 2023, Volume: 24, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro

2023
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
    Reviews in endocrine & metabolic disorders, 2023, Volume: 24, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro

2023
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
    Reviews in endocrine & metabolic disorders, 2023, Volume: 24, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro

2023
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
    Reviews in endocrine & metabolic disorders, 2023, Volume: 24, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro

2023
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
    Reviews in endocrine & metabolic disorders, 2023, Volume: 24, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro

2023
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
    Reviews in endocrine & metabolic disorders, 2023, Volume: 24, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro

2023
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
    Reviews in endocrine & metabolic disorders, 2023, Volume: 24, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro

2023
Pregnancy in patients with adrenocortical carcinoma: a case-based discussion.
    Reviews in endocrine & metabolic disorders, 2023, Volume: 24, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Male; Mitotane; Pregnancy; Retro

2023
Treatment of adrenocortical carcinoma: oncological and endocrine outcomes.
    Current opinion in urology, 2023, 01-01, Volume: 33, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Immunotherapy; Medical Oncology; Mitotan

2023
Treatment of adrenocortical carcinoma: oncological and endocrine outcomes.
    Current opinion in urology, 2023, 01-01, Volume: 33, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Immunotherapy; Medical Oncology; Mitotan

2023
Treatment of adrenocortical carcinoma: oncological and endocrine outcomes.
    Current opinion in urology, 2023, 01-01, Volume: 33, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Immunotherapy; Medical Oncology; Mitotan

2023
Treatment of adrenocortical carcinoma: oncological and endocrine outcomes.
    Current opinion in urology, 2023, 01-01, Volume: 33, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Immunotherapy; Medical Oncology; Mitotan

2023
Central Hypothyroidism is Frequent During Mitotane Therapy in Adrenocortical Cancer Patients: Prevalence and Timeline.
    The Journal of clinical endocrinology and metabolism, 2023, 08-18, Volume: 108, Issue:9

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Hypothy

2023
Adrenocortical Carcinoma: Role of Adjuvant and Neoadjuvant Therapy.
    Surgical oncology clinics of North America, 2023, Volume: 32, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols;

2023
New perspectives for mitotane treatment of adrenocortical carcinoma.
    Best practice & research. Clinical endocrinology & metabolism, 2020, Volume: 34, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Antineoplastic

2020
Next-generation therapies for adrenocortical carcinoma.
    Best practice & research. Clinical endocrinology & metabolism, 2020, Volume: 34, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols;

2020
Adrenocortical carcinoma: current treatment options.
    Current opinion in oncology, 2021, Volume: 33, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols;

2021
Pharmacological profile and effects of mitotane in adrenocortical carcinoma.
    British journal of clinical pharmacology, 2021, Volume: 87, Issue:7

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Antineoplastic Agents, Ho

2021
American Association of Clinical Endocrinology Disease State Clinical Review on the Evaluation and Management of Adrenocortical Carcinoma in an Adult: a Practical Approach.
    Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2020, Volume: 26, Issue:11

    Topics: Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Adult; Humans; Mitotane

2020
How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives.
    Expert opinion on drug metabolism & toxicology, 2021, Volume: 17, Issue:6

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Computer Simula

2021
The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.
    European journal of drug metabolism and pharmacokinetics, 2021, Volume: 46, Issue:5

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Antineoplastic Agents, Hormonal; Biolog

2021
Understanding mitotane mode of action.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2017, Volume: 68, Issue:1

    Topics: Adrenal Cortex; Adrenocortical Carcinoma; Animals; Antineoplastic Agents, Hormonal; Apoptosis; Cell

2017
[Palliative chemotherapy in metastatic adrenal carcinoma beyond the first line: a case report and literature review].
    Medwave, 2017, Jul-31, Volume: 17, Issue:6

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Prot

2017
Benefits of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A Systematic Review and Meta-Analysis.
    BioMed research international, 2018, Volume: 2018

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents,

2018
Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options.
    Expert review of anticancer therapy, 2018, Volume: 18, Issue:11

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2018
Adjuvant and Neoadjuvant Therapy, Treatment for Advanced Disease, and Genetic Considerations for Adrenocortical Carcinoma: An Update from the SSO Endocrine and Head and Neck Disease Site Working Group.
    Annals of surgical oncology, 2018, Volume: 25, Issue:12

    Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Combined Chemothera

2018
Primary malignant tumors of the adrenal glands.
    Clinics (Sao Paulo, Brazil), 2018, 12-10, Volume: 73, Issue:suppl 1

    Topics: Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents,

2018
Update in adrenocortical carcinoma.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:12

    Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Animals; Antineoplastic Agents,

2013
Practical treatment using mitotane for adrenocortical carcinoma.
    Current opinion in endocrinology, diabetes, and obesity, 2014, Volume: 21, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2014
Rare adrenal tumors in children.
    Seminars in pediatric surgery, 2014, Volume: 23, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenal Hyperplasia, Congenital; Adrenalectomy; A

2014
Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma.
    Endocrine pathology, 2014, Volume: 25, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Antineoplastic

2014
Diagnosis, treatment and outcome of adrenocortical cancer.
    The British journal of surgery, 2015, Volume: 102, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hor

2015
Adrenocortical carcinoma.
    Endocrinology and metabolism clinics of North America, 2015, Volume: 44, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents; Antineopla

2015
Surgical management of adrenocortical carcinoma.
    Endocrinology and metabolism clinics of North America, 2015, Volume: 44, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2015
Future directions in the diagnosis and medical treatment of adrenocortical carcinoma.
    Endocrine-related cancer, 2016, Volume: 23, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2016
Letting post-marketing bridge the evidence gap: the case of orphan drugs.
    BMJ (Clinical research ed.), 2016, Jun-22, Volume: 353

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineo

2016
Update on adrenocortical carcinoma management and future directions.
    Current opinion in endocrinology, diabetes, and obesity, 2017, Volume: 24, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Endocrinology; Humans; Immunotherapy; Medical On

2017
Emerging drugs for adrenocortical carcinoma.
    Expert opinion on emerging drugs, 2008, Volume: 13, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Antineoplastic

2008
Adrenocortical cancer treatment.
    Hormone research, 2009, Volume: 71 Suppl 1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Algorithms; Antineoplastic Combined Chemotherapy

2009
Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-20, Volume: 27, Issue:27

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adrenocortical Hyperfunction; Antineoplastic Age

2009
[Mitotane in the treatment of adrenal carcinoma].
    Duodecim; laaketieteellinen aikakauskirja, 2010, Volume: 126, Issue:17

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Mitotan

2010
Practical considerations in the evaluation and management of adrenocortical cancer.
    Seminars in oncology, 2010, Volume: 37, Issue:6

    Topics: Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols; Diagnostic

2010
Androgen- and estrogen-secreting adrenal cancers.
    Seminars in oncology, 2010, Volume: 37, Issue:6

    Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Algorithms; Androgens; Anti

2010
[Management of adrenocortical carcinomas in children].
    Bulletin du cancer, 2011, Volume: 98, Issue:5

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Beckwith-Wiedem

2011
Surgical resection of a virilizing adrenal mass with extensive tumor thrombus.
    The Canadian journal of urology, 2011, Volume: 18, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2011
Contemporary management of adrenocortical carcinoma.
    European urology, 2011, Volume: 60, Issue:5

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2011
Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.
    Clinical endocrinology, 2011, Volume: 75, Issue:5

    Topics: Adrenocortical Carcinoma; Animals; Antineoplastic Agents; Cytochrome P-450 CYP3A; Drug Interactions;

2011
Chemotherapy for advanced adrenal cancer: improvement from a molecular approach?
    BJU international, 2011, Volume: 108, Issue:10

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Antineoplastic Combined C

2011
Metronomic therapy concepts in the management of adrenocortical carcinoma.
    Hormones & cancer, 2011, Volume: 2, Issue:6

    Topics: Administration, Metronomic; Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Animals; Antineoplast

2011
Xenograft models for preclinical drug testing: implications for adrenocortical cancer.
    Molecular and cellular endocrinology, 2012, Mar-31, Volume: 351, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Antineoplastic Agents, Hormonal; Humans

2012
Targeted therapies for adrenocortical carcinoma: IGF and beyond.
    Hormones & cancer, 2011, Volume: 2, Issue:6

    Topics: Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Animals; Antibodies, Monoclonal; Antibodies, Mono

2011
The next generation of therapies for adrenocortical cancers.
    Trends in endocrinology and metabolism: TEM, 2012, Volume: 23, Issue:7

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Mitotan

2012
Development of mitotane lipid nanocarriers and enantiomers: two-in-one solution to efficiently treat adreno-cortical carcinoma.
    Current medicinal chemistry, 2012, Volume: 19, Issue:34

    Topics: Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Drug Carriers; Humans; Lipids; Mitotane;

2012
Pregnancy in a patient with adrenal carcinoma treated with mitotane: a case report and review of literature.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Fatal Ou

2013
[Diagnosis and treatment for adrenocortical carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:3

    Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2004
[Adrenocortical carcinoma and its treatment].
    Postepy higieny i medycyny doswiadczalnej (Online), 2004, Feb-26, Volume: 58

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Combined Chemother

2004
[Recurrent operations on the adrenal glands].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2005, Volume: 76, Issue:3

    Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Anti

2005
Mitotane for adrenocortical carcinoma treatment.
    Current opinion in investigational drugs (London, England : 2000), 2005, Volume: 6, Issue:4

    Topics: Adrenocortical Carcinoma; Humans; Mitotane

2005
Adrenocortical carcinoma.
    Current opinion in oncology, 2006, Volume: 18, Issue:1

    Topics: Activins; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents,

2006
[Adrenocortical carcinoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2006, May-28, Volume: Suppl 1

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Combined Modality Therapy; Cytodi

2006
Adrenocortical carcinoma.
    The Netherlands journal of medicine, 2007, Volume: 65, Issue:2

    Topics: Academic Medical Centers; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combine

2007
[Adrenocortical carcinoma. Diagnostic work-up and treatment].
    Der Urologe. Ausg. A, 2008, Volume: 47, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2008
Adjunctive treatment of adrenocortical carcinoma.
    Current opinion in endocrinology, diabetes, and obesity, 2008, Volume: 15, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Combined Chemother

2008
Bilateral primary adrenal non-Hodgkin's lymphoma and primary adrenocortical carcinoma--review of the literature preoperative differentiation of adrenal tumors.
    Endocrine journal, 2008, Volume: 55, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged, 80

2008
Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature.
    Cancer, 1993, Dec-01, Volume: 72, Issue:11

    Topics: Adolescent; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Age Factors;

1993
Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies.
    Surgical oncology clinics of North America, 1998, Volume: 7, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

1998
Cytotoxic treatment of adrenocortical carcinoma.
    World journal of surgery, 2001, Volume: 25, Issue:7

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Cisplatin; Doxorubicin; E

2001
[Adrenocortical carcinoma].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 7

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Age Factors; Combined Modality Th

2001

Trials

20 trials available for mitotane and Adrenocortical Carcinoma

ArticleYear
Clinical management and outcomes associated with etoposide, doxorubicin, and cisplatin plus mitotane treatment in metastatic adrenocortical carcinoma: a single institute experience.
    International journal of clinical oncology, 2021, Volume: 26, Issue:12

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined

2021
Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.
    ESMO open, 2022, Volume: 7, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols;

2022
Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE.
    European journal of cancer (Oxford, England : 1990), 2023, Volume: 189

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols;

2023
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.
    The lancet. Diabetes & endocrinology, 2023, Volume: 11, Issue:10

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Disease-Free Survival; Humans; Mitotane

2023
Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 08-01, Volume: 39, Issue:22

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Antineoplastic

2021
Comparison of two mitotane starting dose regimens in patients with advanced adrenocortical carcinoma.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:12

    Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Ho

2013
The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
    Hormones & cancer, 2014, Volume: 5, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies,

2014
CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2014
Short-term variation in plasma mitotane levels confirms the importance of trough level monitoring.
    European journal of endocrinology, 2014, Volume: 171, Issue:6

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Case-Control St

2014
Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane.
    Annals of surgical oncology, 2010, Volume: 17, Issue:1

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents,

2010
Mitotane has a strong and a durable inducing effect on CYP3A4 activity.
    European journal of endocrinology, 2011, Volume: 164, Issue:4

    Topics: Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Cytochrome P-450 CYP3A; Enzyme Activat

2011
Mitotane has a strong and a durable inducing effect on CYP3A4 activity.
    European journal of endocrinology, 2011, Volume: 164, Issue:4

    Topics: Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Cytochrome P-450 CYP3A; Enzyme Activat

2011
Mitotane has a strong and a durable inducing effect on CYP3A4 activity.
    European journal of endocrinology, 2011, Volume: 164, Issue:4

    Topics: Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Cytochrome P-450 CYP3A; Enzyme Activat

2011
Mitotane has a strong and a durable inducing effect on CYP3A4 activity.
    European journal of endocrinology, 2011, Volume: 164, Issue:4

    Topics: Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Cytochrome P-450 CYP3A; Enzyme Activat

2011
High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.
    European journal of endocrinology, 2012, Volume: 166, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; Bl

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Combination chemotherapy in advanced adrenocortical carcinoma.
    The New England journal of medicine, 2012, Jun-07, Volume: 366, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherap

2012
Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:10

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents; Antineoplast

2012
No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma.
    Journal of endocrinological investigation, 2012, Volume: 35, Issue:10

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; El

2012
Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
    The Journal of clinical endocrinology and metabolism, 2013, Volume: 98, Issue:1

    Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinom

2013
Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
    Journal of pediatric hematology/oncology, 2006, Volume: 28, Issue:8

    Topics: Administration, Oral; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Ch

2006
Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
    Cancer, 1998, Nov-15, Volume: 83, Issue:10

    Topics: Administration, Oral; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplasti

1998
Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
    Cancer, 2000, Mar-01, Volume: 88, Issue:5

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined

2000
[Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels].
    Medizinische Klinik (Munich, Germany : 1983), 2001, Jul-15, Volume: 96, Issue:7

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Chemothe

2001

Other Studies

174 other studies available for mitotane and Adrenocortical Carcinoma

ArticleYear
The effect of mitotane on viability, steroidogenesis and gene expression in NCI‑H295R adrenocortical cells.
    Molecular medicine reports, 2013, Volume: 7, Issue:3

    Topics: Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Caspase 3; Caspase 7; Cell Line, Tumor; C

2013
Different management of adrenocortical carcinoma in children compared to adults: is it time to share guidelines?
    Endocrine, 2021, Volume: 74, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Prot

2021
Live birth after in-vitro maturation of oocytes in a patient with specific ovarian insufficiency caused by long-term mitotane treatment for adrenocortical carcinoma.
    Reproductive biomedicine online, 2022, Volume: 44, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; In Vitro Oocyte Maturation Techn

2022
Ribociclib Cytotoxicity Alone or Combined With Progesterone and/or Mitotane in in Vitro Adrenocortical Carcinoma Cells.
    Endocrinology, 2022, 02-01, Volume: 163, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aminopyridines; Antineoplastic Agents; Antineopl

2022
Mitotane treatment in adrenocortical carcinoma: mechanisms of action and predictive markers of response to therapy.
    Minerva endocrinology, 2022, Volume: 47, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Biomarkers; Hum

2022
Progression of Vertebral Fractures in Patients with Adrenocortical Carcinoma Undergoing Mitotane Therapy.
    The Journal of clinical endocrinology and metabolism, 2022, 04-19, Volume: 107, Issue:5

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Hydroco

2022
Spironolactone is associated with reduced mitotane levels in adrenocortical carcinoma patients.
    Endocrine-related cancer, 2022, 02-03, Volume: 29, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Male; M

2022
Temporal Trends in Outcomes in Patients With Adrenocortical Carcinoma: A Multidisciplinary Referral-center Experience.
    The Journal of clinical endocrinology and metabolism, 2022, 04-19, Volume: 107, Issue:5

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Mitotan

2022
Successful administration of mitotane (O, p'-DDD) in pediatric oncology.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:7

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Child; Child, Preschool; Drug Monitoring; Female

2022
Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies.
    Endocrine reviews, 2022, 11-25, Volume: 43, Issue:6

    Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Genomics; Humans; Mitotane

2022
Massive adrenocortical carcinoma presenting as peripheral edema: a case report.
    Journal of medical case reports, 2022, Jun-20, Volume: 16, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aged; Edema; Humans; Hydrocortisone; Male; Mitot

2022
[A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission].
    Hinyokika kiyo. Acta urologica Japonica, 2022, Volume: 68, Issue:5

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Prot

2022
Mitotane Targets Lipid Droplets to Induce Lipolysis in Adrenocortical Carcinoma.
    Endocrinology, 2022, 09-01, Volume: 163, Issue:9

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Cell Line, Tumo

2022
Key factors for effective mitotane therapy in children with adrenocortical carcinoma.
    Endocrine-related cancer, 2022, 09-01, Volume: 29, Issue:9

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Child; Female;

2022
Long-term complete remission of metastatic adrenocortical carcinoma.
    Hormone molecular biology and clinical investigation, 2023, Mar-01, Volume: 44, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Combined

2023
CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2/M phase transition, and PANoptosis.
    Journal of translational medicine, 2022, 10-02, Volume: 20, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Apoptosis; Aurora Kinase A; CDC2 Protei

2022
Prognostic factors and mitotane treatment of adrenocortical cancer. Two decades of experience from an institutional case series.
    Frontiers in endocrinology, 2022, Volume: 13

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Androgens; Antineoplastic Agents, Hormonal; Fema

2022
Mitotane With or Without Cisplatin and Etoposide for Patients with a High Risk of Recurrence in Stages 1-3 Adrenocortical Cancer After Surgery.
    Annals of surgical oncology, 2023, Volume: 30, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Antineoplastic

2023
Targeting of a New Node in Lipid Metabolism as a Potential Treatment Strategy for ACC.
    Endocrinology, 2023, 01-09, Volume: 164, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Lipid Droplets; Lipid Metabolism; Lipoly

2023
The management of postoperative disease recurrence in patients with adrenocortical carcinoma: a retrospective study in 106 patients.
    European journal of endocrinology, 2023, Jan-10, Volume: 188, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Mitotan

2023
Favourable prognosis in metastatic adrenal carcinoma: An unexpected outcome.
    JPMA. The Journal of the Pakistan Medical Association, 2022, Volume: 72, Issue:10

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Male; Middle Aged; Mitotane; Prognosis

2022
[Morphological predictors of the efficacy of mitotane therapy in adrenocortical cancer].
    Problemy endokrinologii, 2023, Jan-08, Volume: 68, Issue:6

    Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2023
Inflammation-based scores as predictors of treatment response in advanced adrenocortical carcinoma.
    Endocrine-related cancer, 2023, 04-01, Volume: 30, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Inflammation; Lymphocytes; Middl

2023
Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Female; Humans; Mitotane; Neoplasm Recurrence, L

2023
New Findings on Presentation and Outcome of Patients With Adrenocortical Cancer: Results From a National Cohort Study.
    The Journal of clinical endocrinology and metabolism, 2023, 09-18, Volume: 108, Issue:10

    Topics: Adrenal Cortex Neoplasms; Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Cohort Studies; Female;

2023
Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Androgens; Humans; Hypogonadism; Longitudinal St

2023
[Adrenocortical carcinoma in women of reproductive age].
    Medicina, 2023, Volume: 83, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Female;

2023
[A Case of Aldosterone-Producing Adrenocortical Carcinoma].
    Hinyokika kiyo. Acta urologica Japonica, 2023, Volume: 69, Issue:5

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aldosterone; Humans; Male; Middle Aged; Mitotane

2023
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane.
    Endocrine-related cancer, 2023, 10-01, Volume: 30, Issue:10

    Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; DNA, Bacterial; Humans; Mitotane

2023
Two-dimensional chromatography for enantiomeric analysis of mitotane and its metabolite o,p'-DDA in patients with adrenocortical carcinoma indicates enantioselective metabolism.
    Bioorganic chemistry, 2023, Volume: 141

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Chromatography, High Pressure Liquid; Humans; Mi

2023
Case report: Remarkable response to a novel combination of mitotane, etoposide, paraplatin, and sintilimab in a patient with metastatic adrenocortical carcinoma.
    Frontiers in endocrinology, 2023, Volume: 14

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Carboplatin; Etoposide; Humans; Male; Mit

2023
Adrenocortical carcinoma mimicking pheochromocytoma on iodine 123-labeled metaiodobenzylguanidine scintigraphy.
    Polish archives of internal medicine, 2019, 11-29, Volume: 129, Issue:11

    Topics: Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Four-Dime

2019
The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
    The Journal of clinical endocrinology and metabolism, 2020, 02-01, Volume: 105, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; Ce

2020
A Micellar Mitotane Formulation with High Drug-Loading and Solubility: Physico-Chemical Characterization and Cytotoxicity Studies in 2D and 3D In Vitro Tumor Models.
    Macromolecular bioscience, 2020, Volume: 20, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Cytotoxins; Drug Carriers; Hep G2 Cells; Humans;

2020
Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis.
    Proceedings of the National Academy of Sciences of the United States of America, 2019, 10-29, Volume: 116, Issue:44

    Topics: 3T3 Cells; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Apoptosis; Ferroptosis; HEK2

2019
Clinical presentation, treatment modalities and outcome in patients with adrenocortical carcinoma: A single center experience.
    Neoplasma, 2020, Volume: 67, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols;

2020
A simplified method for therapeutic drug monitoring of mitotane by gas chromatography-electron ionization-mass spectrometry.
    Biomedical chromatography : BMC, 2020, Volume: 34, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Drug Monitoring

2020
[A CASE REPORT: A PATIENT WITH METASTATIC ADRENOCORTICAL CARCINOMA EXCLUSIVELY TREATED WITH MITOTANE WITH LONG-TERM FOLLOW-UP].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2019, Volume: 110, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aged; Antineoplastic Agents, Hormonal; Follow-Up

2019
Involvement of 27-Hydroxycholesterol in Mitotane Action on Adrenocortical Carcinoma.
    Cells, 2020, 04-04, Volume: 9, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Apoptosis; Cell Line, Tumor; Cell Survival; Fema

2020
Liver X receptor inhibition potentiates mitotane-induced adrenotoxicity in ACC.
    Endocrine-related cancer, 2020, Volume: 27, Issue:6

    Topics: Adrenocortical Carcinoma; Apoptosis; Female; Humans; Liver X Receptors; Middle Aged; Mitotane; Trans

2020
Ovarian cyst formation in women of reproductive age receiving mitotane as part of the treatment of adrenocortical carcinoma: Clinical and experimental observations.
    Acta obstetricia et gynecologica Scandinavica, 2020, Volume: 99, Issue:10

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Amenorrhea; Antineoplastic Agents, Hormon

2020
Mitotane liposomes for potential treatment of adrenal cortical carcinoma:
    Pharmaceutical development and technology, 2020, Volume: 25, Issue:8

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Biological Availability; Chemistry, Pha

2020
Expression of SOAT1 in Adrenocortical Carcinoma and Response to Mitotane Monotherapy: An ENSAT Multicenter Study.
    The Journal of clinical endocrinology and metabolism, 2020, 08-01, Volume: 105, Issue:8

    Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Antineopla

2020
Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth.
    Molecular cancer therapeutics, 2020, Volume: 19, Issue:9

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Antineoplastic Agents, Hormonal; Choles

2020
Population Pharmacokinetic and Pharmacogenetic Analysis of Mitotane in Patients with Adrenocortical Carcinoma: Towards Individualized Dosing.
    Clinical pharmacokinetics, 2021, Volume: 60, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Liver-S

2021
Extra-adrenal, non-functional adrenocortical carcinoma presenting with acute abdomen: a case report.
    Journal of medical case reports, 2020, Jul-08, Volume: 14, Issue:1

    Topics: Abdomen, Acute; Adolescent; Adrenal Glands; Adrenocortical Carcinoma; Antineoplastic Agents, Hormona

2020
Ectopic adrenocortical carcinoma of the ovary: An unexpected outcome.
    Annales d'endocrinologie, 2020, Volume: 81, Issue:5

    Topics: ACTH Syndrome, Ectopic; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Ag

2020
Metabolic and hormonal side effects of mitotane treatment for adrenocortical carcinoma: A retrospective study in 50 Danish patients.
    Clinical endocrinology, 2021, Volume: 94, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Denmark; Humans

2021
A case report of neurological adverse events caused by short-term and low-dose treatment of mitotane: The role of therapeutic drug monitoring.
    Medicine, 2020, Oct-02, Volume: 99, Issue:40

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Asian People; D

2020
Predicitve Value of FDG Uptake in the Remaining Adrenal Gland Following Adrenalectomy for Adrenocortical Cancer.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2021, Volume: 53, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Aged

2021
A rare case of right shoulder pain.
    BMJ case reports, 2021, Feb-10, Volume: 14, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Fatal Ou

2021
In vitro cytotoxic effect of a chitin-like polysaccharide produced by Mortierella alpina on adrenocortical carcinoma cells H295R, and its use as mitotane adjuvant.
    In vitro cellular & developmental biology. Animal, 2021, Volume: 57, Issue:4

    Topics: Adrenocortical Carcinoma; Animals; Cell Line, Tumor; Cell Proliferation; Chitin; Chlorocebus aethiop

2021
Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Prot

2021
Combination of Mitotane and Locoregional Treatments in Low-volume Metastatic Adrenocortical Carcinoma.
    The Journal of clinical endocrinology and metabolism, 2021, 10-21, Volume: 106, Issue:11

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; An

2021
Japanese single-institution analysis of mitotane for patients with adrenocortical carcinoma.
    Endocrine journal, 2021, Dec-28, Volume: 68, Issue:12

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Humans; Japan;

2021
Long-Term Outcomes of Adjuvant Mitotane Therapy in Patients With Radically Resected Adrenocortical Carcinoma.
    The Journal of clinical endocrinology and metabolism, 2017, Apr-01, Volume: 102, Issue:4

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Aged, 80

2017
The aurora kinase inhibitor AMG 900 increases apoptosis and induces chemosensitivity to anticancer drugs in the NCI-H295 adrenocortical carcinoma cell line.
    Anti-cancer drugs, 2017, Volume: 28, Issue:6

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols;

2017
Complete Responses to Mitotane in Metastatic Adrenocortical Carcinoma-A New Look at an Old Drug.
    The oncologist, 2017, Volume: 22, Issue:9

    Topics: Adrenal Cortex Neoplasms; Adrenal Insufficiency; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and

2017
Long-Term Survival in a Patient With Metastatic DDR2-Positive Adrenal Cortical Carcinoma.
    Clinical genitourinary cancer, 2017, Volume: 15, Issue:5

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Carboplatin; Combined Modality Th

2017
Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma.
    The Journal of pharmacy and pharmacology, 2017, Volume: 69, Issue:11

    Topics: Adipose Tissue; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Ho

2017
Adding metyrapone to chemotherapy plus mitotane for Cushing's syndrome due to advanced adrenocortical carcinoma.
    Endocrine, 2018, Volume: 61, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antimetabolites, Antineoplastic; An

2018
Time Until Partial Response in Metastatic Adrenocortical Carcinoma Long-Term Survivors.
    Hormones & cancer, 2018, Volume: 9, Issue:1

    Topics: Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Moda

2018
High-Dose Mitotane-Induced Encephalopathy in the Treatment of Adrenocortical Carcinoma.
    The oncologist, 2018, Volume: 23, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Brain Di

2018
Use of a levonorgestrel-releasing intrauterine device for menorrhagia treatment during adjuvant therapy of adrenocortical carcinoma with mitotane.
    Ginekologia polska, 2017, Volume: 88, Issue:10

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Chemothe

2017
Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma.
    The Journal of clinical endocrinology and metabolism, 2018, 04-01, Volume: 103, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic A

2018
The GRP78/BiP inhibitor HA15 synergizes with mitotane action against adrenocortical carcinoma cells through convergent activation of ER stress pathways.
    Molecular and cellular endocrinology, 2018, 10-15, Volume: 474

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Caspases; Cell Line, Tumor; Cell Proliferation;

2018
Prognostic factors in adrenocortical carcinoma: data from a large Polish series.
    Polish archives of internal medicine, 2018, 06-30, Volume: 128, Issue:6

    Topics: Adrenocortical Carcinoma; Adult; Aged; Female; Humans; Male; Middle Aged; Mitotane; Mitotic Index; P

2018
CYP11B1 has no role in mitotane action and metabolism in adrenocortical carcinoma cells.
    PloS one, 2018, Volume: 13, Issue:5

    Topics: Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Proliferation; Hum

2018
Long-term survival in recurrent adrenocortical cancer.
    BMJ supportive & palliative care, 2019, Volume: 9, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Adult; Antineoplastic Combined C

2019
Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients.
    European journal of endocrinology, 2018, 10-16, Volume: 179, Issue:5

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents,

2018
Mitotane-induced dyspnoea: an unusual side effect.
    BMJ case reports, 2018, Sep-01, Volume: 2018

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aged; Antineoplastic Agents, Hormonal; Diagnosis

2018
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
    European journal of endocrinology, 2018, 10-01, Volume: 179, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2018
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
    European journal of endocrinology, 2018, 10-01, Volume: 179, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2018
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
    European journal of endocrinology, 2018, 10-01, Volume: 179, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2018
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors
    European journal of endocrinology, 2018, 10-01, Volume: 179, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2018
Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane.
    Molecular and cellular endocrinology, 2019, 01-15, Volume: 480

    Topics: Adenine; Adrenocortical Carcinoma; Cell Line; Computer Simulation; Drug Synergism; Gene Expression R

2019
In vitro antitumor activity of progesterone in human adrenocortical carcinoma.
    Endocrine, 2019, Volume: 63, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Apoptosis; beta

2019
A case report of a TDM-guided optimization of mitotane for a safe and effective long-term treatment.
    Journal of chemotherapy (Florence, Italy), 2019, Volume: 31, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Dose-Res

2019
Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
    International journal of oncology, 2019, Volume: 54, Issue:6

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols;

2019
Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical carcinoma at high risk of recurrence.
    European journal of endocrinology, 2019, Jun-01, Volume: 180, Issue:6

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents,

2019
A clinical study and treatment results of adrenocortical carcinoma patients presented in Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore.
    JPMA. The Journal of the Pakistan Medical Association, 2019, Volume: 69, Issue:5

    Topics: Adolescent; Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcino

2019
Changes in total and acylated ghrelin levels during mitotane treatment in patients with adrenocortical carcinoma.
    Polish archives of internal medicine, 2019, 08-29, Volume: 129, Issue:7-8

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adrenocorticotropic Hormone; Adult; Antineoplast

2019
National Treatment Practice for Adrenocortical Carcinoma: Have They Changed and Have We Made Any Progress?
    The Journal of clinical endocrinology and metabolism, 2019, 12-01, Volume: 104, Issue:12

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged; Antineoplastic Agents; Anti

2019
Development and internal validation of an adrenal cortical carcinoma prognostic score for predicting the risk of metastasis and local recurrence.
    Clinical endocrinology, 2013, Volume: 79, Issue:4

    Topics: Adolescent; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineo

2013
Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.
    Endocrine-related cancer, 2013, Volume: 20, Issue:3

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents;

2013
Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
    European journal of endocrinology, 2013, Volume: 169, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplas

2013
Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
    European journal of endocrinology, 2013, Volume: 169, Issue:3

    Topics: Adolescent; Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineo

2013
Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
    Molecular and cellular endocrinology, 2013, Dec-05, Volume: 381, Issue:1-2

    Topics: Administration, Oral; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Antineoplastic Ag

2013
Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines.
    Molecular and cellular endocrinology, 2014, Jan-25, Volume: 382, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols;

2014
Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer.
    European urology, 2014, Volume: 65, Issue:4

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents,

2014
Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma.
    The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:2

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Aged, 80

2014
Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
    Endocrine-related cancer, 2014, Volume: 21, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Albumins; Animals; Antineoplastic Combined Chemo

2014
Therapy of adrenocortical cancer with o,p' DDD in two children.
    The Journal of clinical endocrinology and metabolism, 1963, Volume: 23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Dichlorodiphenyldichloroe

1963
Hair cortisol measurement in mitotane-treated adrenocortical cancer patients.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2014, Volume: 46, Issue:4

    Topics: Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Body Mass Index; Case-Control Studies; Fem

2014
Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome.
    European journal of endocrinology, 2014, Volume: 170, Issue:6

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents;

2014
Development of a pharmacokinetic model of mitotane: toward personalized dosing in adrenocortical carcinoma.
    Therapeutic drug monitoring, 2015, Volume: 37, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; Ar

2015
The lack of antitumor effects of o,p'DDA excludes its role as an active metabolite of mitotane for adrenocortical carcinoma treatment.
    Hormones & cancer, 2014, Volume: 5, Issue:5

    Topics: Adrenal Cortex; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Apoptosis; Cell Line, Tumor; Cel

2014
Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells.
    Endocrine, 2014, Volume: 47, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antibiotics, Antineoplastic; Antineoplastic Agen

2014
Metastatic adrenocortical carcinoma with a prolonged response to mitotane.
    Oncology (Williston Park, N.Y.), 2014, Volume: 28, Issue:7

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2014
Marked transient hypercholesterolemia caused by low-dose mitotane as adjuvant chemotherapy for adrenocortical carcinoma.
    Journal of atherosclerosis and thrombosis, 2014, Volume: 21, Issue:12

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; C

2014
Ovarian macrocysts and gonadotrope-ovarian axis disruption in premenopausal women receiving mitotane for adrenocortical carcinoma or Cushing's disease.
    European journal of endocrinology, 2015, Volume: 172, Issue:2

    Topics: Adolescent; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Biomarkers; Female; Go

2015
Risk of adrenocortical carcinoma in adrenal tumours greater than 8 cm.
    World journal of surgery, 2015, Volume: 39, Issue:5

    Topics: Adenoma; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Antineoplas

2015
Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma.
    The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:8

    Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2015
A case report of a solitary pancreatic metastasis of an adrenocortical carcinoma.
    BMC surgery, 2015, Jul-31, Volume: 15

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2015
Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells.
    Endocrinology, 2015, Volume: 156, Issue:11

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Apoptosis; Cell

2015
Sunitinib monotherapy instead of mitotane combination therapy for the treatment of refractory adrenocortical carcinoma.
    International journal of urology : official journal of the Japanese Urological Association, 2015, Volume: 22, Issue:11

    Topics: Adrenocortical Carcinoma; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Female; Humans; Indo

2015
Subacute Cutaneous Lupus Erythematosus Induced by Mitotane.
    JAMA dermatology, 2016, Volume: 152, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Female; Follow-

2016
Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells.
    Endocrine, 2016, Volume: 52, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Cell Line, Tumo

2016
Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
    European journal of endocrinology, 2016, Volume: 174, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; Ce

2016
Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
    Oncotarget, 2016, Jan-19, Volume: 7, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carci

2016
Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
    Journal of the American College of Surgeons, 2016, Volume: 222, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Agent

2016
Adrenocortical carcinoma: Retrospective analysis of the last 22 years.
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2016, Volume: 63, Issue:5

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adult; Aged; Chemothe

2016
Discussion.
    Journal of the American College of Surgeons, 2016, Volume: 222, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Female; Humans;

2016
Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature.
    Medicine, 2016, Volume: 95, Issue:13

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; beta Catenin; C

2016
Efficacy and safety of mitotane in the treatment of adrenocortical carcinoma: A retrospective study in 34 Belgian patients.
    Annales d'endocrinologie, 2016, Volume: 77, Issue:5

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Anti

2016
FATE1 antagonizes calcium- and drug-induced apoptosis by uncoupling ER and mitochondria.
    EMBO reports, 2016, Volume: 17, Issue:9

    Topics: Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Apoptosis; Calcium; DNA-Binding Proteins;

2016
Preclinical progress and first translational steps for a liposomal chemotherapy protocol against adrenocortical carcinoma.
    Endocrine-related cancer, 2016, Volume: 23, Issue:10

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Animals; Antineoplastic Combined Ch

2016
Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
    The Journal of clinical endocrinology and metabolism, 2016, Volume: 101, Issue:12

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Anti

2016
[Adjuvant mitotane treatment after adrenalectomy is not beneficial for adrenocortical carcinoma].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2016, Volume: 87, Issue:11

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Chemotherapy, Adjuvant; Combined

2016
Multi-Target Approach to Metastatic Adrenal Cell Carcinoma.
    Archives of Iranian medicine, 2016, Volume: 19, Issue:9

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Combin

2016
Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.
    Hormones & cancer, 2016, Volume: 7, Issue:5-6

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Bortezomib; Cel

2016
Adrenocortical Cancer: A Molecularly Complex Disease Where Surgery Matters.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Oct-15, Volume: 22, Issue:20

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Antineoplastic

2016
Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
    Oncotarget, 2016, Nov-29, Volume: 7, Issue:48

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Biomarkers, Tumor; Cell Line, Tumor; Ci

2016
Early progression under mitotane and polychemotherapy does not mean failure in adrenocortical carcinoma patient.
    Annales d'endocrinologie, 2017, Volume: 78, Issue:1

    Topics: Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Carboplatin; Drug Therapy, Combination; E

2017
Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Endocrine-related cancer, 2008, Volume: 15, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; CDC2 Protein Ki

2008
Impact of standardised reporting in adrenocortical carcinoma: a single centre clinicopathological review.
    Journal of clinical pathology, 2008, Volume: 61, Issue:8

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic A

2008
Systemic chemotherapy for adrenocortical carcinoma: comparative responses to conventional first-line therapies.
    Anti-cancer drugs, 2008, Volume: 19, Issue:6

    Topics: Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease

2008
Successful treatment of adrenocortical carcinoma with pulmonary metastasis in a child: report of a case.
    Surgery today, 2008, Volume: 38, Issue:10

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2008
Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma.
    The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Animals; Cell Line, Tumor; Cell Proliferation; F

2009
A patient with ectopic cortisol production derived from malignant testicular masses.
    Nature clinical practice. Endocrinology & metabolism, 2008, Volume: 4, Issue:12

    Topics: Adrenal Rest Tumor; Adrenocortical Carcinoma; Adrenocorticotropic Hormone; Aged; Cushing Syndrome; H

2008
Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study.
    Clinical endocrinology, 2010, Volume: 72, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adrenocorticotropic Hormone; Adult; Antineoplast

2010
How is adrenocortical cancer being managed in the UK?
    Annals of the Royal College of Surgeons of England, 2009, Volume: 91, Issue:6

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2009
Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy.
    Clinical medicine & research, 2009, Volume: 7, Issue:1-2

    Topics: Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free S

2009
Management of adrenocortical carcinoma.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2009, Volume: 7, Issue:7

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Catecholamines;

2009
Development of microemulsion of mitotane for improvement of oral bioavailability.
    Drug development and industrial pharmacy, 2010, Volume: 36, Issue:4

    Topics: Administration, Oral; Adrenocortical Carcinoma; Animals; Antineoplastic Agents, Hormonal; Biological

2010
The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane.
    Endocrine-related cancer, 2010, Volume: 17, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Algorithms; Anti

2010
Mitotane serum level analysis; good agreement between two different assays.
    Clinical endocrinology, 2010, Volume: 73, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Blood Chemical

2010
Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-10, Volume: 28, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Combined Modali

2010
Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
    Endocrine-related cancer, 2010, Volume: 17, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Combined Chemotherapy Prot

2010
Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation.
    International journal of oncology, 2010, Volume: 37, Issue:2

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Cell Proliferation; Cyclin B; Cyclin-Dependent K

2010
Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers.
    The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:11

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Anti

2010
What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?
    Clinical endocrinology, 2010, Volume: 73, Issue:5

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Humans; Ki-67 Antigen; Mitotane; Neoplasm Recurr

2010
Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.
    The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:6

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic A

2011
Pregnancy in a patient with adrenocortical carcinoma during treatment with Mitotane - a case report.
    Endokrynologia Polska, 2011, Volume: 62, Issue:2

    Topics: Abortion, Induced; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents,

2011
Normal adrenal function in an infant following a pregnancy complicated by maternal adrenal cortical carcinoma and mitotane exposure.
    Journal of pediatric endocrinology & metabolism : JPEM, 2011, Volume: 24, Issue:3-4

    Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2011
Metastatic adrenocortical carcinoma presenting simultaneously with Cushing's and Conn's syndromes: a case report.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:11

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Aged; Antineoplastic Combined Chemotherapy Proto

2011
[Adrenocortical carcinomas: therapeutic advances in 2011].
    Annales d'endocrinologie, 2011, Volume: 72 Suppl 1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Antineoplastic Combined C

2011
Simultaneous analysis of mitotane and its main metabolites in human blood and urine samples by SPE-HPLC technique.
    Biomedical chromatography : BMC, 2012, Volume: 26, Issue:11

    Topics: Administration, Oral; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hor

2012
Mitotane exhibits dual effects on steroidogenic enzymes gene transcription under basal and cAMP-stimulating microenvironments in NCI-H295 cells.
    Toxicology, 2012, Aug-16, Volume: 298, Issue:1-3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Cell Line, Tumo

2012
A fly in the ointment: reassessing mitotane's role in the treatment of adrenocortical carcinoma.
    Pharmacogenomics, 2012, Volume: 13, Issue:11

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Biomarkers, Pharmacological; Clinical Trials as

2012
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 7

    Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; A

2012
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 7

    Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; A

2012
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 7

    Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; A

2012
Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 7

    Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; A

2012
ADRENOCORTICAL CARCINOMA TREATED WITH O,P' -DDD.
    British medical journal, 1965, May-22, Volume: 1, Issue:5446

    Topics: Adrenal Gland Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Child; Cushing Syndrome; D

1965
The effect of o,p'-DDD therapy on plasma cholesterol in adrenal carcinoma.
    Proceedings of the staff meetings. Mayo Clinic, 1961, Nov-22, Volume: 36

    Topics: Adrenal Gland Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Cholesterol; Dichlorodiphenyldich

1961
[Features of clinical presentation of malignant adrenocortical tumor cortex metabolism over time].
    Likars'ka sprava, 2003, Issue:8

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormon

2003
[Histoculture drug response assay guided concurrent chemoradiotherapy for lung metastasis from adrenocortical carcinoma--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Combined Chemotherapy Protocols;

2004
[Practical use of o,p'DDD in adrenocortical carcinoma].
    Bulletin du cancer, 2005, Volume: 92, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Female;

2005
Dendritic cells as potential adjuvant for immunotherapy in adrenocortical carcinoma.
    Clinical endocrinology, 2006, Volume: 65, Issue:2

    Topics: Adjuvants, Immunologic; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antigens, Neoplas

2006
Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
    The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:11

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Antineoplastic Agents, Hormonal; Chemothe

2006
[Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma].
    Endokrynologia, diabetologia i choroby przemiany materii wieku rozwojowego : organ Polskiego Towarzystwa Endokrynologow Dzieciecych, 2006, Volume: 12, Issue:3

    Topics: Adrenal Cortex Neoplasms; Adrenal Glands; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal;

2006
Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma.
    European journal of radiology, 2008, Volume: 66, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Combined Modali

2008
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane treatment for adrenocortical carcinoma.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane therapy of adrenal cancer - use and controversy.
    The New England journal of medicine, 2007, Jun-07, Volume: 356, Issue:23

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Tailored hormonal therapy in secretory adrenocortical cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:7

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Aged; Aldosterone; Alkalosis; Ang

2007
Adjuvant mitotane in adrenocortical carcinoma.
    The New England journal of medicine, 2007, Sep-20, Volume: 357, Issue:12

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane in adrenocortical carcinoma.
    The New England journal of medicine, 2007, Sep-20, Volume: 357, Issue:12

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane in adrenocortical carcinoma.
    The New England journal of medicine, 2007, Sep-20, Volume: 357, Issue:12

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Adjuvant mitotane in adrenocortical carcinoma.
    The New England journal of medicine, 2007, Sep-20, Volume: 357, Issue:12

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Chemotherapy, A

2007
Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane.
    Endocrine-related cancer, 2008, Volume: 15, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Biomarkers, Tum

2008
Adrenocortical carcinoma. A clinical study and treatment results of 52 patients.
    Cancer, 1995, May-15, Volume: 75, Issue:10

    Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Car

1995
[Bilateral gynecomastia revealing malignant feminizing adrenocortical carcinoma].
    Annales d'endocrinologie, 1994, Volume: 55, Issue:1

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Diagnosis, Differential; Feminization; Gynecomas

1994
Mitotane in adrenocortical carcinoma.
    British journal of cancer, 1994, Volume: 70, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Chemotherapy, Adjuvant; Humans; Mitotane

1994
Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients.
    British journal of cancer, 1994, Volume: 69, Issue:5

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Child; Child, Preschool

1994
Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Two years later.
    Cancer, 1996, Oct-01, Volume: 78, Issue:7

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Chemotherapy, Adjuvant; Female; Follow-Up

1996
Changes in neoplastic cell features and sensitivity to mitotane during mitotane-induced remission in a patient with recurrent, metastatic adrenocortical carcinoma.
    Endocrine-related cancer, 1999, Volume: 6, Issue:4

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents, Hormonal; Dehydroepiandro

1999
Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.
    World journal of surgery, 2001, Volume: 25, Issue:7

    Topics: Adolescent; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Aged, 80 and over; Anti

2001
Hyperadrenocorticism associated with excessive sex hormone production by an adrenocortical tumor in two dogs.
    Journal of the American Veterinary Medical Association, 2001, Dec-15, Volume: 219, Issue:12

    Topics: Adrenal Cortex Neoplasms; Adrenalectomy; Adrenocortical Carcinoma; Adrenocortical Hyperfunction; Adr

2001
A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
    Cancer, 2002, May-01, Volume: 94, Issue:9

    Topics: Administration, Oral; Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplasti

2002